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ABSTRACT
Cryptococcus neoformans is an opportunistic fungal pathogen, infecting mainly
immunocompromised individuals. As the main cause of cryptococcosis, it is responsible
for over 180,000 deaths every year. As an environmental yeast, it has unique adaptations
that allow it to proliferate in the human host. Among these adaptations its capacity to
transition to an extreme phenotype known as Titan cells is of special interest to
researchers. With sizes above 10 um and able to reach 70 um or more in cell size. This
size is accompanied with a large vacuole, larger polysaccharide capsule, and an
increased resistance to fluconazole (FLC). FLC is a fungistatic drug that is widely used
to treat cryptococcosis, so any mechanism that confers resistance to fluconazole is of the
utmost importance to understand. Protocols to develop titanization in vitro have been
developed, allowing the study of Titan cells in a laboratory setting, but questions remain.
This dissertation utilizes two in vitro titanization protocols to answer if only C.
neoformans can titanize. Multiple members of the Cryptococcus spp. were subjected to
titanization protocols and analyzed to confirm if they had all characteristics described for
Titan cells. This dissertation shows that titanization is unique to the members of the C.
neoformans and its sister species C. gattii. Other Cryptococcus spp. could generate Titanlike cells but did not exhibit all the defined characteristics. This dissertation also highlights
minimum conditions that contribute to titanization in vitro. While previous titanization
protocol relied on serum, here we present a serum-free protocol that induces titanization
in vitro and allowed us to analyze these Titan cells. In particular pH was found to be of
importance for titanization. An optimal pH for titanization was found to be ~7.3, while
slightly acidic pH (5.5) prevents titanization but is conducive to proliferation of yeast cells
ii

and a relatively alkaline (8.0) inhibits proliferation. This dissertation establishes that pH
response is critical for Titan cell formation, and that conditions that inhibit proliferation are
enough for titanization.
Additionally, this dissertation characterizes two cell cycle control kinases, SWE1
and SWE102. These genes are homologs of the cell cycle regulator SWE1 in
Saccharomyces cerevisiae. The cell cycle in budding yeast, S. cerevisiae, is regulated by
the morphogenesis checkpoint kinase Swe1, which inhibits cyclin dependent kinase
(CDK), by phosphorylation, prior to mitosis and during stress. SWE1 and SWE102 were
knocked out individually, generating single deletion mutants. These mutants
demonstrated that Swe1 and Swe102 can phosphorylate CDK1 in C. neoformans and
can recover the phenotype in a S. cerevisiae swe1∆ strain phosphorylating CDK1 in it as
well. The single deletion mutants also show increased sensitivity to antifungals, heat
stress response, and surprisingly to DNA damage by genotoxic chemicals. Elimination
of SWE1 and SWE102 appears to be synthetic lethal. To circumvent this, a copper
regulated promoter (CTR4) was introduced as the promoter for Swe1, while Swe102 was
knocked out in the same C. neoformans strains. Treating this CTR4 promoter strain and
the single deletion mutants with DNA damaging agents resulted in the treated cells
becoming resistant to FLC and showing aneuploidy and increase in ploidy levels, both of
which have been associated with FLC resistance. The single deletions were able to
titanize, with the swe1∆ demonstrating an irregular-looking capsule and swe102∆ shows
an elongated cell body phenotype and capsule formation. We provide an analysis of the
myriad roles Swe1 and Swe102 have in cell cycle control, stress response,
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and morphological transitions demonstrating the importance of studying the cell cycle to
better understand the pathogenesis of C. neoformans.
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I. Literature Review
I.I Cryptococcosis

Fungal infections have become more commonplace since the mid-20th century,
causing mycotic disease in humans, with cases in the millions worldwide [1] [2].
Unfortunately, fungi weren’t considered as medically important pathogens until the
1980s and the advent of the AIDS pandemic. Due to this late recognition,
investigations of fungal diseases lag behind the studies on bacteria, viruses, and even
some parasites. The challenge of treating fungal infections is compounded by a lack
of licensed vaccines for fungi, effective diagnostic methods limited to only the most
common mycoses, and drug limitations. This last one is insidious because some
drugs are linked to an intrinsic or acquired resistance, they tend to be toxic due to
both the patient and the fungi being eukaryotes, and they are expensive with limited
companies manufacturing the antifungals.
Among fungal infections, those caused by the Cryptococcus neofomans/gattii
species complex result in over 180,000 deaths annually [3]. This is infection is known
as cryptococcosis. Cryptococcosis is a deadly disease, with most people affected
being immunocompromised individuals [4] [5], with a notable exception being an
ongoing outbreak in Vancouver Island, British Columbia, Canada [6]. While
cryptococcosis has a worldwide distribution and has been reported on since the 1890s
[7], it was not until the 1970s that it became an “awakening mycosis” due to advances
in organ transplantation, immunosuppressive treatments, and a higher incidence of
cancer [8]. When the AIDS pandemic began, cryptococcosis was one of the more
1

common fungal infections [9], with up to 80% of worldwide cryptococcosis cases being
associated to HIV/AIDS [10].
Originally classified as two varieties of the same fungal species, the two varieties
were resolved into 7 different species clustered into two species complexes. This
most recent classification is based on the genotyping of eleven genetic loci,
susceptibility to antifungals, and prevalence in patient groups. We will go into more
detail on how these species are divided below, in sections 1.2 and 1.3.

I.I.A Infectious route, symptoms, and treatment

Cryptococcus neoformans/gattii enters the body through the respiratory system.
Desiccated, haploid yeast cells or basidiospores [11] enter the body and quickly
become encapsulated. Once encapsulated the yeast cells are deposited in the lungs.
In the lungs, cryptococcal cells can be neutralized by the host defense, resulting in a
self-limiting infection [12]. In immunocompetent individuals, pulmonary clearance
depends on the formation and resolution of granulomas. The alveolar macrophages
are ineffective against C. neoformans (Fig. 1.1). Due to this, macrophages need to be
recruited, to the lung, and activated by C4+ T-cell signals. These mature macrophages
are known as M1. The M1 macrophages resolve the infection by trapping and
degrading the cryptococcal infectious particle through the formation of granulomas
(Fig. 1.1) [13]. If the infection cannot be cleared due a compromised immune system,
C. neoformans can disseminate through the host and reach the brain. In the brain it
causes a lethal meningoencephalitis [12].
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Figure 1. 1 Cryptococcus neoformans/gattii infectious route and resolution by
alveolar macrophages.
A) Desiccated C. neoformans is inhaled by the host. It quickly forms a capsule and
proceeds to the lungs [11]. B) Encapsulated yeasts are deposited in the alveoli, where
they cause pulmonary cryptococcosis. C) In immunocompetent individuals’ alveolar
macrophages can recruit macrophages to battle infection. D) Infection is resolved by the
formation and clearance of granulomas [13]. Created with Biorender.com

In immunocompromised individuals the infection will not be cleared due to
deficiencies in their immune response. Others may have been infected while they were
immunocompetent but diseases, such as HIV/AIDS, have allowed for a latent infection to
be reactivated. These infections exist in granulomas that were never cleared [8]. These
3

infections or reactivations, result in the yeasts traveling to the head, crossing the blood
brain barrier (BBB) and causing a meningoencephalitis (Fig. 1.2) [14] [8].

Figure 1. 2: Cryptococcus neoformans reaches the brain by crossing the blood
brain barrier.
When C. neoformans reaches the brain, it must cross the blood brain barrier, a highly
selective, semi-permeable border that prevents solutes from crossing into the
cerebrospinal fluid, where neurons and the actual brain are found. Created with
Biorender.com
Regarding symptoms, how they present will be dependent on what phase of the
disease we are discussing. During the pulmonary phase, up to one-third healthy hosts
will have an asymptomatic colonization of the lungs. It can be diagnosed by a chest Xray and presence of noncalcified nodules [8]. The other 2/3 of healthy hosts may present
an acute and self-limiting pneumonia [15]. For immunocompromised hosts, the
4

cryptococcal pneumonia is symptomatic [15] (cough, shortness of breath, fever, chest
pain) and if left untreated may result in acute respiratory distress syndrome (ARDS).
ARDS is a condition where the alveoli fill with fluid with symptoms like severe shortness
of breath, unusual, labored, and rapid breathing, low blood pressure, and confusion and
extreme fatigue [16]. The central nervous system (CNS) phase of the infection can
present with headaches, facial neuropathies, memory loss, and meningeal irritation
among others [8] [17]. A cryptococcoma, a cryptococcal granuloma in the brain, may form
in the most severe cases [18]. This stage of the disease can be easily diagnosed by
lumbar puncture, where the cerebrospinal fluid is collected and observed for the presence
of C. neoformans.
Treatment for cryptococcosis is divided into three phases: induction, consolidation,
and maintenance. These phases last 2 weeks, 8 weeks, and 6-12 months respectively.
The treatment is the same regardless of HIV/AIDS status and if the patient is a
nontransplant patient. During induction, amphotericin B (AMB) is given at 0.7-1.0
mg/kg/day and 5-flucytosine (5-FC) is given at 100 mg/kg/day [19]. The consolidation
phase consists of giving fluconazole 400 mg/kg/day, while the maintenance phase
consists of giving fluconazole 200 mg/kg/day for at least 6 months. Treatment is
summarized Table 1.1. Drugs used during treatment are described in Table 1.2
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Table 1. 1 Cryptococcosis treatment. Treatment is divided into three phases and
consists of 3 different anti-fungal drugs. Treatment is described, in detail, in the text.
Treatment

phase Induction:

length
Drugs

2 weeks
and

dosage Amphotericin B 0.7-1.0 mg/kg/day

used

5-FC 100 mg/kg/day

Maintenance:

Consolidation:

8 weeks

6-12 months

Fluconazole:

Fluconazole:

400mg/kg/day

200mg/kg/day

Table 1. 2 Antifungal drugs and mechanism of action. Amphotericin B, 5-flucytosine,
and fluconazole are essential drugs for the treatment of cryptococcosis
Drug

Type of Drug

Amphotericin B

Polyene: binds to ergosterol, destabilizing the
fungal cell membrane and allows pores to form.
Metabolites interferes with RNA biosynthesis,

5-FC

preventing the production of essential proteins. It
also inhibits DNA synthesis
A

Fluconazole

triazole

demethylase.

that

inhibits

This

the

inhibition

enzyme
prevents

14αthe

conversion of lanosterol to ergosterol. This results
in the accumulation of 14α-methyl sterols, thus
preventing fungal growth
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Cryptococcus neoformans and Cryptococcus gattii complexes

Cryptococcus neoformans is a species complex of two closely related species, C.
neoformans and C. deneoformans [20]. Cryptococcus gattii has also been
phylogenetically resolved into a species complex with multiple species: Cryptococcus
gattii, C. bacillisporus, C. deuterogattii, and C. decagattii. The C. gattii species are known
to cause cryptococcal infections, mostly, in immune-competent individuals [21] [22]. Even
though

C.

neoformans

and

C.

deneoformans

cause

infections

mostly

in

immunocompromised individuals, it is C. neoformans that causes the majority of
cryptococcal disease and deaths [23].
Previously, all the C. neoformans and C. gattii species were grouped into two
species. These species being C. neoformans and C. gattii. Distinguishing between these
species was based around the usage of a selective growth media, called Canavanine
Glycine Blue (CGB) agar. Canavanine is a non-proteinogenic amino acid that is
structurally related to L-arginine [24]. All C. gattii species are resistant to canavanine and
can assimilate glycine. Cryptococcus deneoformans cannot grow on canavanine, and
only 33% of C. neoformans can tolerate canavanine. The latter cannot assimilate glycine.
The current classification based on the clustering of species into genotypic groups
[25], based on amplified fragment length polymorphism (AFLP), a technique that allows
for the detection of polymorphisms in different genomic regions at the same time. How
they are divided based on AFLP can be found in Table 1.3.
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I.I.B Cryptococcus neoformans species complex
Cryptococcus neoformans was first described in 1894 by the German physician
Busse and Buschke from a “sarcoma-like” lesion in a female patient’s tibia [7]. At the
same time, Italian physician Sanfelice isolated an encapsulated yeast in fermented peach
juice [26] and from the infected lymph node of an ox [27]. Once the encapsulated yeast
was established as a member and the type species for the genus Cryptococcus, it
received the current species name Cryptococcus neoformans. Serological analyses
established separate varieties of C. neoformans: C. neoformans var. neoformans and C.
neoformans var. grubii [28] and C. gattii [29] [30]. The classification system for serotypes
established C. neoformans as serotype A, C. neoformans var. neoformans as serotype
D, C. gattii was classified as B and C. Current phylogenetic analyses has separated
serotypes and varieties of Cryptococcus neoformans into two species: C. neoformans
(previously var. grubii) and C. deneoformans (previously var. neoformans) [31] [32].
Cryptococcus neoformans (AFLP1, AFLP1A, AFLP1B)
This species is the most commonly occurring species, comprising 63% of all C.
neoformans/C. gattii worldwide isolates. Over 52% of these isolates come from HIVinfected patients and 16% from immunocompetent people [33]. Of all the species in both
complexes, it is better at growing at 37˚C and producing more melanin. While having a
bigger capsule than C. deneoformans, on average it is smaller than the capsule formed
by members of the C. gattii species complex. [34].
Cryptococcus deneoformans (AFLP2)
This species comprises 5% of all worldwide isolates, with 1.6% coming from HIV8

infected patients and 0.2% from immunocompetent patients [33]. It is more often involved
in soft-tissue infections, while C. neoformans is associated with systematic mycoses. Its
preference for soft tissue most likely relates to its sensitivity to heat. Not tolerating 37˚C
allows for this species to be easily cleared by fever [32].

I.I.C Cryptococcus gattii species complex
Cryptococcus gattii was first described in 1896 by Curtis [35] but it wasn’t until
1970 that it received its current name of C. gattii [36]. The complex was of no major clinical
significance, until an outbreak of cryptococcosis in Vancouver Island, British Columbia,
Canada.
Cryptococcus gattii (AFLP3)
This species comprises 9% of all worldwide isolates. Of these, 6% come from
immunocompetent patients and only 0.4% come from HIV-infected patients. It has a
worldwide distribution like C. neoformans, with Australia reporting the most C. gattii
isolates, both clinical and environmental. The capsular size for this strain was found to be
bigger than those produced by C. deuterogattii and C. deneoformans. It has the lowest
mean MICs for fluconazole, when compared to C. deuterogattii. This suggest that
fluconazole could be a good treatment for cryptococcosis caused by this species [37] [25].
Cryptococcus bacillisporus (AFLP4)
This species makes up 4% of all globally collected isolates, with 3% of these from
clinical cases and 6% environmentally isolated. Like other C. gattii species, it infects
immunocompetent patients with only 0.4% of isolates coming from HIV-infected patients
[33]. It produces a capsule bigger than that of the main pathogenic species, C.
9

neoformans. Its capsule is also larger, than the main pathogenic gattii species, C.
deuterogattii. Surprisingly, it grows best at 30˚C. This lower thermal tolerance could
explain why it is unable to cause systemic disease [34].
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Table

1.

3

Cryptococcus

neoformans

and

Cryptococcus

gattii

species

classification and incidence. Summarized classification and percentage of isolates of
C. neoformans and C. gattii.
Species

AFLP

Serotype

Group

Incidence
(Percentage

of

all

C.

neoformans/gattii isolated)
C. neoformans

AFLP1,
AFLP1A,

63% of all isolates recovered.
A

Worldwide distribution.

AFLP1B
C. deneoformans

AFLP2

D

5% of all isolates recovered

C. gattii

AFLP4

B

9% of all known isolates

C. bacillisporus

AFLP5

C

4% of all known isolates

C. deuterogattii

AFLP6

B

13% of all known isolates

C. tetragattii

AFLP7

C

1% of all isolates recovered.

C. decagattii

AFLP10

B

Unknown.
Only 5 isolates are known of.

Cryptococcus deuterogattii (AFLP5)
This species is a major emerging pathogen which mainly infects immunocompetent
humans and animals. It is the causative agent of an ongoing outbreak in Vancouver
Island, British Columbia, Canada, and the Pacific Northwest of the USA. This species
11

makes up 13% of worldwide isolates, with 35% of these being of environmental origin
[33]. It is also comprising 47% of all C. gattii isolates. It is predominately isolated from
HIV-negative individuals, and mostly causes pulmonary disease.
Cryptococcus tetragattii (AFLP6) and Cryptococcus decagattii (AFLP10)
For C. tetragattii, we know that it comprises 1% of worldwide isolates. For C. decagattii
there are only 5 known isolates. They are both considered extremely rare species and
information on their distribution is lacking. Most of the C. gattii complex species isolated
from Africa belong to C. tetragattii while C. decagattii was isolated first in Mexico. [25].

I.I.D What makes Cryptococcus neoformans/gattii pathogens?
Being environmental fungi that are also opportunistic pathogens of humans, C.
neoformans/gattii utilize virulence factors that allow adaptation to both the harsh natural
environment and the harshness of the human body. Chief among these virulence factors
are adaptation to host temperature, capsule formation, and melanin production. These
three virulence factors are the most studied and well understood [12] [38] [39]. It has been
proposed that morphological changes should be also considered a virulence factor, [12]
[40] [41] [42], especially since the discovery and characterization of morphologically
distinct Titan cells have been shown to help C. neoformans/gattii survive and proliferate
in the host. [43].
Polysaccharide capsule
The cryptococcal capsule contributes 25% of the total virulence composite, the
total aggregate of proteins, genes, and processes that allow C. neoformans/gattii to cause
disease [44] [38]. The capsule is composed of two main polysaccharides,
12

glucuronoxylomannan (GXM, ~90%), and galactoxylomannan (GalXM, ~10%), and
mannoproteins. In the soil environment, C. neoformans/gattii use the polysaccharide
capsule to prevent complete desiccation [45]. The capsule can also be used to defend
the yeast from predators such as amoeba from the genus Acanthamoeba [46].
The capsule contributes to virulence through multiple mechanisms. The capsule is
anti-phagocytic [44] and a negative immune modulator. Various studies have proposed
different mechanisms to explain these observations. GXM is believed to be polyanionic,
allowing it to inhibit phagocytosis by electrostatic repulsion. Due to no phagocytosis
happening, less antigen is presented to T-cells. This way the host immune response is
reduced [47]. GXM also inhibits inflammation by inducing the secretion of interleukin (IL)
10. IL-10 secretion interferes with cell-mediated immunity by preventing the activation of
T-cell mediated control of C. neoformans [48]. Another observation is that the capsule
prevents access to C. neoformans epitopes found on the cell wall [49] [50].
Polysaccharide can also be secreted into the host tissues, causing inhibition of neutrophil
migration, inhibition of the exit of leukocytes from blood vessels and prevents said
leukocytes from binding to endothelium [12]. These qualities help protect the yeast from
antibody or complement-derived opsonins.

I.I.E Adaptation to host conditions

Environmental fungi are not able to grow at high temperatures, with the inside of
mammalian hosts being especially inhibitory to them. Uniquely, Cryptococcus
neoformans/gattii has multiple virulence factors that allow it to proliferate in the host.
Among these, C. neoformans/gattii have a heat shock stress response to deal with the
host internal temperature [51] [52] [53] and urease production [54]. Urease production
13

allows for C. neoformans/gattii survival inside phagolysosome, with the lowering of pH
and production of ammonia being important for this survival.
Melanin
The melanins are negatively charged, hydrophobic pigments of high molecular
weight that are formed by oxidative polymerization of phenolic and/or indole compounds.
Cryptococcus neoformans/gattii melanizes during infection [55] [56], conferring
resistance to ROS and the microbial peptides produced by macrophages [57] [58].
Cryptococcal melanin is deposited in the fungal cell wall, and, after the capsule, it
contributes up to 14% of the fungal virulence composite. [59] [60].

I.I.F Morphogenetic changes: yeasts, hyphae, pseudohyphae, and Titan cells

The yeast form of C. neoformans is the most studied morphotype. With a characteristic
capsule and melanin production, it is the main form found in infected tissue and the
environment. It is characterized by being uniformly globose, usually a single bud, and
measuring on average 4.0-7.0 μm x 4.0-7.0 μm [32]. Bigger cells, up to 9.0 μm, are
present as well during infection or in culture (Fig. 1)
Hyphae are mostly formed during sexual reproduction, where hyphae of different
strains fuse together to fuse their nuclei. From here basidiospores are formed. Curiously,
the formation of hyphae in infected tissue have been rarely reported [61] [42]. This is most
likely related to the high temperature (≥ 37˚C) inside the host, which has a suppressive
effect on filamentous growth [62]. Hyphae in C. neoformans contain clamp connections,
characteristic structures that only the Basidiomycetous fungi have. This clamp connection
allows for the migration of nuclei from one cellular compartment to another.
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Pseudohyphae are a less common morphotype that forms in response to nutrient
deprivation and is strain specific [63]. Pseudohyphae has also been reported from
environmental isolates interacting with Acanthamoeba polyphaga [41] and A.
palestinensis [64]. In these studies, the pseudohyphal form prevented phagocytosis by
the amoeba. Pseudohyphae have been described as having a varying morphology, which
can look like associated and elongated yeast-like cells or look like hypha-like structures
that contain constricted septa (Fig. 1). The hyphae and pseudohyphae morphotypes have
attenuated virulence as demonstrated in experiments in mice [40] [65].

Figure 1. 3 Main Morphotypes of Cryptococcus neoformans.
Cryptococcus neoformans has three main morphotypes. The yeast form is the most
widely known morphotype. The hyphal form is most seen during sexual reproduction. The
pseudohyphal form is characterized by adhered yeast cells, with the bud not being
released from the previous cell. Created with BioRender.com
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The most recently described morphotype of C. neoformans/gattii are Titan cells [66].
These cells are the result of a peculiar morphogenesis in C. neo/gat. While
morphogenesis in the dimorphic fungi results in a transition from hyphal to yeast growth,
C. neoformans undergoes an enlargement where the cell body can increase from around
4-6 μm to 40-50 μm in cell body size alone [66]. If the capsule is taken into consideration,
the size can be in the 70-100 μm range. It is believed that titanization allows individual
cells to evade phagocytosis, since the resulting size is too big for macrophages to engulf
[67]. This could be the reason why Titan cells are so hardy. Another change characteristic
to titans is the cell wall and capsule structure modifications that occur during titanization.
These changes seem to modify the epitopes presented, making it harder for macrophage
recognition to happen [68] [69]. Titan cells also become more resistant to stressors, which
helps the yeast to persist in the host. They cannot disseminate easily due to their large
size, but they produce normal size daughter cells that can spread through the host [43].
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Figure 1. 4 Titan cells are too large to be phagocytized and produce normal size
haploid or aneuploid daughter cells.
Titan cells are characterized by a big vacuole (white and shadowed figure inside titan
cell), that pushes the nucleus and other organelles toward the cell wall. The nucleus can
be seen as light blue, next to cell wall. Created with BioRender.com

Titan cells are vital for C. neoformans infection, survival, and proliferation in mice
models [70] [43]. We described above how the capsule could play a role in survival of
Titan cells. Another factor that could help explain titan cell hardiness is the increased
ploidy that happens during titanization. We must keep in mind that changes in ploidy can
results in changes in cell size and gene expression, possibly enhancing survival [67].
Previous research has shown that ploidy increases are associated with fluconazole
resistance [71]. When Titan cells have progeny (Fig. 1.3), a rapid genome reduction
occurs. This reduction results in the haploid daughter cells. These daughters are more
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likely to be resistant to fluconazole [67]. This resistance seems to be, in part, due to an
aneuploid phenotype that develops in the daughters of Titan cells [67]. The exact
mechanisms of titan cell formation and their contributions to virulence and drug resistance
remain obscure. Therefore, more studies are necessary to better understand this
important morphotype.
Following are some of the key questions related to titan cell biology. Can other
members of the Cryptococcus genus produce Titan cells? Are the members of C.
neoformans species complex and the C. gatti species complex unique in their capacity to
form Titan cells? The Cryptococcus genus contains pathogenic and non-pathogenic fungi.
Are they all able to titanize using the recently developed in vitro [72] [73] titanization
protocols? What are the minimal in vitro conditions that are sufficient to stimulate titan cell
formation? We address these questions in Chapter 2 and 3 of this dissertation.

I.I.G Cell Cycle and Morphogenesis

The morphogenetic changes in C. neoformans, between all four main
morphotypes, rely on control of the cryptococcal cell cycle. This can be observed in
titanization, where the increase in ploidy begins with a cell cycle arrest at G2 [74].
Monokaryotic hyphae is a type of asexual reproduction, where a haploid hyphae form and
spores develop. This type of hyphae forms following cell cycle arrest at G2, which can be
induced by high temperature [75]. It is clear from these examples that a tight control over
the cell cycle is needed for these types of morphogenetic changes to occur.
The eukaryotic cell cycle is tightly regulated and highly conserved. Surveillance
mechanisms known as checkpoints [76]. The checkpoints (Fig.1.4) ensure that a phase
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transition has been completed before the next stage of the cell cycle can start. When a
possible error is detected, a checkpoint becomes active by arresting the cell cycle in the
current stage and prevents replication and/or division. The canonical checkpoints are the
G1/S or restriction checkpoint, the G2/M or DNA damage checkpoint, and the spindle
assembly checkpoint (SAC). [77] [78 [79 [80] [81] [82]. In S. cerevisiae [83] [80] [80].
The Wee1 family are a group of kinases, belonging to the serine/threonine kinases.
They are highly conserved, nuclear tyrosine kinases, which are mostly active during S/G2
phase [84] [85]. It was discovered for the first time in Schizosaccharomyces pombe as a
cell division cycle (cdc) -wee1 mutant. Fission yeast missing Wee1 have a characteristic
smaller than normal cell size [86], hence the name “wee” has been applied. The Wee1
family negatively regulates the activity of the cyclin dependent kinases (CDK). The CDKs
are known as Cdc2 in S. pombe, Cdc28 in S. cerevisiae, and Cdk1 in C. neoformans.
In contrast to budding yeast, S. cerevisiae, in the fission yeast, S. pombe, there is
no morphogenesis checkpoint. S. pombe Wee1 is in control of mechanisms that
coordinate cell growth and cell division [87] [88]. To delay entry into mitosis, Wee1
phosphorylates Cdc2 in a “highly conserved tyrosine residue” at the N-terminus (TYR15).
This happens inside the cell’s nucleus. The Cdc25 phosphatase removes the inhibitory
phosphorylation, this way activating Cdc2 and pushing the cell cycle through (Fig. 1.5).
In wee1- (wee1∆) mutants, the cells fail to alter their critical size threshold at the G2/M
transition in response to lack of nutrients. This gives weight to the hypothesis that Wee1
functions in the pathways that establish cell-size [87] [89]. At the same time, when DNA
is damaged by ionizing radiation, the DNA damage checkpoint results in a G2 mitotic
delay, which allows DNA repair [90].
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Figure 1. 5 Wee1 phosphorylates Cdk1 to arrest the cell cycle and Cdc25 lifts this
block.
Wee1 phosphorylates Cdk1 at a TYR15. This inhibits CDK activity, which can only be
lifted by the Cdc25 phosphatase. Inhibition of Cdk1 happens inside the nucleus. See text
for in-depth description. Created with BioRender.com.

The Morphogenesis Checkpoint’s function is to delay nuclear division when a bud
has not yet formed (Fig. 1.6). In S. cerevisiae, this delay happens due to the
phosphorylation of the cyclin dependent kinase (CDK), Cdc28 [83]. Cdc28 is
phosphorylated at TYR-19 by the Wee1-family kinase Swe1 [91] [92]. Swe1 is transcribed
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in late G1/early S phase only and needs to be degraded before division can happen [92]
[93]. When the cell is stressed enough that a bud does not form, Swe1 stabilizes and
maintains Cdc28 phosphorylation until the stress is resolved. When the stress is resolved,
or under normal conditions, Swe1 localizes to the mother-bud neck, where it is
phosphorylated. This phosphorylation tags Swe1 for degradation. This localization
depends on a group of scaffolding proteins, known as septins. The septins form an
hourglass structure at the yeast bud neck, where multiple proteins localize. Swe1 is
brought to the bud neck by Hsl7 [80] [94], a methyl transferase, which with Hsl1 (septin
binding protein) anchors Swe1 to the bud neck allowing its phosphorylation, and
ultimately degradation (Fig. 1. it [95]. Studies into Swe1 have deleted the gene, creating
a swe1∆ strain. Under normal conditions, Swe1 is not needed for the growth of S.
cerevisiae. However, when budding is inhibited by incubating cells with an actin
depolymerizer, Latrunculin B, nuclear division is blocked based on Swe1-dependent
checkpoint. In Latrunculin B-treated cells lacking Swe1, the nucleus undergoes division
causing binucleated phenotype [83]. It is also reported that overexpression of Swe1 in S.
cerevisiae causes an elongation of the yeast, without cell division happening [96]. This
phenotype is similar to pseudohyphae.
While the bulk of research into Wee1 activity has concentrated on the G2/M
transition, current research points to a role for Wee1 in the S phase checkpoint. Wee1
has a role in the stabilization and protection of stalled replication forks. Wee1 prevents
excessive DNA degradation, by inhibiting excessive DNA2 nuclease activity [97]. By
limiting DNA2-degradation of DNA at the stalled forks, Wee1 allows for the stalled fork to
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be resolved. Among other functions, Wee1 controls “nucleotide pools” by limiting the
amount of CDK-driven origin firing [98].

Figure 1. 6 Swe1 inhibits nuclear division when actin is perturbed. When cell
recovers, Swe1 is localized to the bud neck to be degraded.
With an intact Swe1, in S. cerevisiae, nuclear division and cell division are coupled. This
makes sure that only one nucleus is present in each individual cell. Created with
BioRender.com
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Figure 1. 7 The swe1Δ S. cerevisiae strain is incapable of inhibiting nuclear division
when budding is inhibited.
Created with BioRender.com

As stated above, the research on the cell cycle control in C. neoformans has
concentrated on its specific roles in morphogenetic changes. The literature is lacking on
the existence of a morphogenesis checkpoint in C. neoformans and what roles, if any,
Swe1 may have in it. The literature search results in only two papers referring to Swe1
homologs in C. neoformans. There are two homologs in C. neoformans, annotated as
Swe1 and Swe102. Swe1 in C. neoformans has been reported as essential for
cryptococcal survival in the presence of mouse cerebrospinal fluid [99], while a swe102∆
strain was reported as being less virulent than wild-type in the Galleria mellonella and the
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mice host models of infection [100]. Swe102 was also reported to be essential for
response to antifungal drugs such as fluconazole and for high temperature stress
response. Besides that, there is no literature on a morphogenesis checkpoint, or reports
on Swe1 and/or Swe102 and their function. Regarding a cryptococcal morphogenesis
checkpoint, previous research in our laboratory have observed that C. neoformans does
not need septins to grow under normal conditions [101].

Figure 1. 8 Swe1 and Cdc28 shuttle out of the nucleus and Swe1 localizes to
the bud neck in anticipation of degradation.
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Swe1 degradation is a necessary step for cell division to continue. The septin
scaffold is necessary for the protein complexes that bind to Swe1 to localize and
prepare Swe1 for ubiquitination and subsequent degradation.

I.II Summary

In the following chapters, I present work on the capacity for titanization in C.
neoformans/gattii and whether this capacity extends to other members of Cryptococcus
spp., on the minimal requirements needed for titanization C. neoformans/gattii in vitro,
and the characterization of the Swe1 homologs in C. neoformans. In Chapter two, we
demonstrate, based on two previously described methods [72] [73], that titanization is a
phenotype unique to C. neoformans/gattii, with other members of Cryptococcus spp.
being incapable of it. Chapter three is dedicated to establishing the minimal in vitro
conditions needed for titanization to occur. We developed a Serum-free protocol for
titanization, while other protocols use a 10% fetal bovine serum (FBS) solution as an
induction media. The most surprising result in this chapter is the finding that pH has a
critical role in titanization. The pH of a titanization induction media must be close to 7.3.
When pH is 5.5, cells do not titanize and proliferate robustly. When pH is higher (8.0), it
has an inhibitory effect on the C. neoformans cells. This finding supports a hypothesis
that restrictive proliferation of C. neoformans in 5% CO2 is sufficient to induce titanization
in both C. neoformans and C. gattii.
We dedicate Chapter 4 to characterization of the Wee1 homologs, Swe1 and Swe102,
in C. neoformans, with specific attention given to their roles in titanization and stress
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responses. To our knowledge, this is the first study into the myriad roles of the Wee1
homologs in C. neoformans.
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II.1 INTRODUCTION:

Basidiomycetous yeasts are an ecologically heterogeneous group of fungi that
includes both saprophytic as well as pathogenic species. A significant fraction of the latter
group comprises of human and animal pathogens, including such genera as
Cryptococcus, Malassezia, Rhodotorula, and Trichosporon [1]. In particular, members of
the Cryptococcus neoformans and Cryptococcus gattii species complex are the
etiological agents of fatal systemic mycoses. The C. neoformans species complex
includes C. neoformans var. grubii (serotype A, currently considered a separate species
named C. neoformans) and C. neoformans var. neoformans (serotype D, currently
considered separate species named C. deneoformans) [2] [3]. The C. gattii species
complex includes five genetically distinct groups that have been recently recognized as
separate species (VGI, C. gattii; VGII, C. deuterogattii; VGIII, C. bacillisporus; VGIV, C.
tetragattii; VGIV/VGIIIc, C. decagattii) [2] [3]. In recent years, nearly one million cases of
cryptococcal meningitis occur annually resulting in over 600,000 deaths globally.
Moreover, cryptococcosis is responsible for 15–17% AIDS-related deaths on a global
scale [4] [5]. While C. neoformans can cause mainly opportunistic infections in
immunocompromised patients, representatives of the C. gattii species complex are
capable of infecting also immunocompetent individuals. [6] [7] [8] [9]. Moreover, it is well
established that C. neoformans is responsible for the majority of cryptococcal infections,
while C. deneoformans is less common [8]. Among Cryptococcus species outside of the
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C. neoformans/C. gattii species complex, the following species have been described as
causing occasional infections in humans: C. laurentii [10] [11] [12] [13] , C. albidus [10]
[14] [15] [16], C. curvatus [17] [18], C. uniguttulatus [19], and C. adeliensis [20]. Such
casuistic infections, reviewed in literature most recently by Smith et al. [21] can be also
systemic in case of strains able to grow at 37°C. What makes those selected
Cryptococcus species capable of infecting humans is an important question, the answer
to which remains incomplete. Among the best-described cryptococcal characteristics
necessary for pathogenicity are the ability to proliferate at 37°C, melanisation, formation
of capsule, and the capability of hydrolyzing urea [9] [22]. Most of the above-mentioned
“virulence factors” can be observed together only in representatives of the C.
neoformans/C. gattii species complex, what could potentially explain the basis of their
evolutionary success as pathogens [23] [24].
Dimorphism is one of the common features of human fungal pathogens. A welldocumented example of a dimorphic switching critical for pathogenicity is yeast to hypha
transition characteristic for dimorphic fungi clustered within five genera [23] [24].
Morphological transition of C. neoformans/C. gattii species complex to form enlarged cells
termed Titan cells is a particularly striking manifestation of a perfect adaptation to evade
the mammalian immune system and enhance dissemination in the host [25]. Typically, C.
neoformans cells range in size from 4 to 6 μm, whereas the size larger than 10 μm has
been considered as indicative of titanization. Other key features of Titan cells are thicker
cell wall, single large vacuole, and increased ploidy within a single nucleus [26] [27] [28].
Furthermore, Titans can produce daughters of “normal” size, which can be haploid or
frequently aneuploid [29]. Titan cells are resistant to phagocytosis due to the enlargement
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of the cell body [25] [26] [30]. Moreover, it has been demonstrated that Titan cells and
aneuploid daughter cells of Titans show increased resistance to many physico-chemical
factors and toward some drugs commonly used in the therapy of cryptococcosis [29].
However, titanization may not be required for pathogenicity as some clinical isolates of
C. neoformans are presumably not capable of undergoing this morphological transition
[32] [33] [34]. Therefore, it remains unclear to what extent titanization is important for
human cryptococcosis and whether this striking characteristic is unique to pathogenic
Cryptococcus species, especially since titanization has never been studied in species
outside of the C. neoformans/C. gattii species complex.
Recent investigations led to considerable advances in our understanding of the
nature of titanization, by uncovering external stimuli that are sufficient and genes that are
essential for this morphological transition [32] [33] [34]. Two well-documented pathways
involved in titanization are the cAMP-mediated signaling (dependent on Gpr4/Gpr5
receptors, adenylyl cyclase Cac1, Pka1 kinase, and the transcription factor Rim101) and
the mating pathway [27] [35] [36]. Until recently the progress in identifying more regulators
has been hampered by the lack of a suitable in vitro system. However, recently published
work from several laboratories delivered new opportunities towards a thorough
understanding of titanization by developing in vitro conditions capable of stimulating this
morphological change [32] [33] [34]. This breakthrough research led to the identification
of novel positive (Gat201, Ada2, Cap59, Cap60, Ric8, Sgf29, Lmp1) and negative
(Usv101, Pkr1, Tsp2) regulators that were important for titanization under specific
conditions [32] [34]. These studies also led to an overarching conclusion that titanization
can be stimulated by a variety of external signals, including CO2, hypoxia, exposure to
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serum (specifically two serum components, phospholipids, and bacterial peptidoglycan),
and quorum sensing [32] [33] [34]. Importantly, these novel protocols to induce titanization
in vitro have provided an opportunity to test to what extent is the ability to form Titans
conserved in other Cryptococcus species. Based on a survey of 23 strains that represent
10 basidiomycetous yeast species outside of the C. neoformans/C. gattii species
complex, we postulate that C. neoformans/C. gattii species complex is unique among
other basidiomycetous yeasts in regard to the ability to form bona fide Titan cells.

II.2 MATERIALS AND METHODS

Tested strains and media

All the strains used in this study are listed in Table 2.1, which includes information
about the origin (source), place of primary isolation, and actual taxonomic position for
each tested strain. Strains were routinely cultured on YPD (Yeast extract Peptone
Dextrose) semi-solid medium, followed by liquid medium: 1% yeast extract, 2% bactopeptone and in case of semi-solid media 2% bacto-agar (BD Difco, Sparks, MD, USA,
cat. no. REF212720, REF211820, and REF212720) and filter-sterilized 2% glucose
(VWR International LLC, West Chester, PA, USA, cat. no. BDH0230). In case of Titan
induction experiment, cells were grown overnight in 5 ml YNB (Yeast Nitrogen Base)
liquid medium: 0.67% Yeast Nitrogen Base with amino acids, pH 5.5 (Sigma cat. no.
Y1250,

St.

Louis,

MO,

USA),

2%

at 30°C with horizontal shaking at 220 rpm (Thermo Scientific, MAXQ4450).

39

glucose

In vitro Titan cell induction

Titan cells were generated in vitro according to two recently described protocols.
To follow the protocol by Dambuza et al., experiments were performed in sterile, non-heat
inactivated 10% Fetal Bovine Serum (FBS, Sigma, cat. no. F6178) diluted in 1×
concentrated PBS (Dulbecco`s Phosphate-Buffered Saline w/o Ca2+ and Mg2+, cat. no.
REF21-031-CV, Corning Cell-gro®, Manassas, VA, USA), at final pH equal to 7.4.
Original concentrated FBS was normally stored in 2.5 ml aliquots at −20°C to prevent the
repeated freeze-thaw procedure. Cells were incubated in static conditions for 48 h or 120
h at 37 or 30°C under 5% CO2 atmosphere (New Brunswick an Eppendorf company,
Galaxy 170 S, Ayrshire, Scotland). To follow the protocol according to Hommel et al., cells
were initially incubated in 10 ml of the YPD liquid medium at 30°C with horizontal shaking
at 150 rpm (Thermo Scientific, MAXQ4450) for 22 h. Subsequently, cultures were
centrifuged (5 min, 3,000 rpm, room temperature) and the cells were washed twice using
sterile liquid MM medium: 15 mM D-glucose, 10 mM MgSO4, 29.4 mM KH2PO4, 13 mM
Glycine and 3.0 μM Thiamine (Sigma cat. no.G8270, M7506, P5655, G7126 and T4625,
respectively). Finally, cells were resuspended in 1 ml of MM medium in 1.5 ml Eppendorf
tubes to achieve density equal to 104cells/ml (based on calculations in haemocytometer).
Cell suspensions prepared in this way were incubated for 5 days at 30°C with horizontal
shaking at 800 rpm (Eppendorf Thermomixer, Eppendorf, Poland).
Evaluation of cell viability

Viability of cells was evaluated qualitatively by examination of micro-wells of the
titration plate directly under the microscope and quantitatively by plating. For this purpose,
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100 μl volume from each micro-well of the titration plate was collected (after mixing) and
either initially diluted if necessary, using sterile 1× concentrated PBS or directly spread
on YPD semi-solid medium. Plates were incubated 48 h at 30°C in the incubator w/o CO2
(Thermo Scientific, Heratherm Incubator IMH180, Langenselbold, Germany). After this
time plates were photographed, and colony counting was performed.
Negative staining with nigrosin

For polysaccharide capsule visualization, negative staining technique with 10%
nigrosin solution (nigrosine 10%, formalin 0.5% in water) was used [37]. This method
permits visualization of the transparent and unstainable capsule in the case of
Cryptococcus spp. For this purpose, 5 μl of nigrosin solution and 5 μl of dense yeast liquid
culture was mixed on the surface of the microscopic slide and covered with a thin cover
glass. Microscopic preparations were examined using immersion oil and magnification
1000× under the light microscope (OPTA-TECH, model: MB200) with a built-in camera
for photographic documentation (OPTA-TECH, 3MP) and interfaced with OptaView-IS
software (OptaView-IS, version 3.6.6)
Microscopy and imaging

Microscopic observations were performed under the Axiovert 200M microscope
using either the 20× or 100× objective (ID#M 202086, Carl Zeiss MicroImaging, Inc.,
Thornwood, NY, USA) with a built-in camera for photographic documentation (AxioCam
HRm) and interfaced with AxioVision Rel 4.8 software (Carl Zeiss, Thornwood, NY). For
evaluation of cell body diameter at least 100 cells for each treatment were measured

41

based on the images using ImageJ (https://imagej.nih.gov/ij/) and the data were plotted
using the GraphPad Prism v. 8 software.
Construction of the phylogenetic tree

The multiple sequence alignment of the nuclear ribosomal internal transcribed
spacer (ITS) region was performed based on CLUSTALW software as implemented on
the GenomeNet (https://www.genome.jp/tools-bin/clustalw). All the sequences (see
Appendix 1) used to construct a phylogenetic tree were obtained from the GenBank of
the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA).
Alignment and phylogenetic reconstructions were performed using the function “build” of
ETE3 v3.1.1. [38] The Phylogenetic tree (Figure 2.1) was constructed using fasttree with
slow NNI and MLACC = 3. [39] Values at nodes are SH-like local support. Scale bar
indicates one substitution per 10 nucleotide positions.
Statistical analysis

To test differences between the median of cell body diameter, first the Normality
Kolmogorov-Smirnov test was performed and subsequently the Mann-Whitney and
Kluskal-Wallis tests were performed with the use of GraphPad Prism v. 8 software.

II. 3Results

Phylogenetic relatedness of the tested species

We tested the following eight non-neoformans/non-gattii Cryptococcus species for
their ability to undergo titanization in vitro: C. albidus (2 strains), C. aspenensis (4 strains),
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C. curvatus (2 strains), C. kuetzingii (1 strain), C. laurentii (5 strains), C. terrestris (4
strains), C. terreus (1 strain), and C. uniguttulatus (two strains). We also tested
representative strains from the C. gattii species complex (seven strains). To include other
basidiomycetous yeasts outside of the Cryptococcus genus, we tested two species of
Malassezia: M. furfur (1 strain) and M. sympodialis (1 strain). We also included one
reference strain of Saccharomyces cerevisiae as a representative of ascomycetous
yeasts. All strains utilized in this study are listed in Table 2.1

Figure 2. 1 Phylogenetic tree illustrating the relatedness of the species included
in this study.
Values at nodes are SH-like local support. Scale bar indicates one substitution per 10
nucleotide positions.
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Table 2. 1 Strains used in this study. Their source, place of primary isolation, and
actual taxonomic position are indicated#. Each strain has been tested for the ability
to proliferate at 37°C.

Cryptococcus albidusa
MD22
Cryptococcus albidusa
MD41
Cryptococcus
aspenensisb
DS573
Cryptococcus
aspenensisb
DS572
Cryptococcus
aspenensisb
DS570
Cryptococcus
aspenensisb
DS569
Cryptococcus
curvatusc
MD110/2009
Cryptococcus
curvatusc
MD120/2009
C. deuterogattiid
R265 (CBS10514)
Cryptococcus bacillisporus
WM161
Cryptococcus bacillisporus
CA1053
Cryptococcus bacillisporus
B4546
Cryptococcus bacillisporus
CA1508
Cryptococcus bacillisporus
NIH312/ATCC34880
Cryptococcus tetragattii
MMRL2651

Grow
th at Ref
37°C
1
Interdigital spaces of the feet,
[40]
component of the skin mycobiome No
(healthy male, Poland)
1
Groin skin, component of the skin
[40]
mycobiome
(healthy
female, No
Poland)
2
[41]
Populus tremuloides, New York
No
State (USA)
2
[41]
Populus tremuloides, New York
No
State (USA)
2
[41]
Populus tremuloides, New York
No
State (USA)
2
Populus tremuloides, New York
[41]
Yes
State (USA)
1
Soil, Olsztyn, Poland
[40]
No
Source(1-5), primary isolation

Strain

,
,
,
,
,
,

1

Soil, Olsztyn, Poland

No

3

Bronchial washings of infected
patient from the Vancouver Island, Yes
British Columbia, Canada, VGIIa
2

Yes

2

Clinical isolate, VGIIIa, CA

Yes

2

VGIIb

Yes

2

Yes
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[42]

[43]

Environmental isolate, VGIIIa, San
Diego CA,

Clinical isolate, VGIIIb, CA
2
Clinical isolate from cerebrospinal
fluid, VGIIIb
2
Clinical isolate, VGIV, Botswana

[40]

Yes
Yes

[43]
[43]
[43]
[43]
[43]

Cryptococcus
kuetzingiia*
MUCL27749
Cryptococcus laurentiie , DS620
laurentiie

Cryptococcus
, DS619
e
Cryptococcus laurentii , DS621
Cryptococcus laurentiie , DS288
Cryptococcus laurentiie , DS386
Cryptococcus neoformansf
H99 (var. grubii) (ATCC 208821)
Cryptococcus neoformansf
MD31 (var. grubii)
Cryptococcus terrestrisg , DS291
Cryptococcus terrestrisg , DS233
Cryptococcus terrestrisg , DS234
Cryptococcus terrestrisg , DS290
Cryptococcus
DUMC177.8
Cryptococcus
MD29

terreush
uniguttulatusi

Cryptococcus
uniguttulatusi
MD26
Malassezia furfurj , CBS7019

2

Intestinal tract, Blatta orientalis

No

Picea abies, New York State (USA)

2

Picea abies, New York State (USA)
Picea abies, New York State (USA)
2
Colophospermum
mopane,
Botswana
2
Colophospermum
mopane,
Botswana
2
Male patient with Hodgkin's
disease, New York, USA
1
Bronchoalveolar lavage (BAL) of
patient with AIDS, Poland
2
Colophospermum
mopane,
Botswana
2
Colophospermum
mopane,
Botswana
2
Colophospermum
mopane,
Botswana
2
Colophospermum
mopane,
Botswana
, 2Soil, New Zealand
2

Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
No
No
No
No

1

Interdigital spaces of the feet,
component of the skin mycobiome No
(healthy female, Poland)
, 1Soil, Wroclaw, Poland
No
,

Malassezia sympodialisk
ATCC42132
Saccharomyces
BY4741

2

cerevisiael

4

Skin of 15-year-old girl
pityriasis versicolor, Finland

with Yes

4

Skin of a male with pityriasis Yes
versicolor
5

Euroscarf, Germany (isogenic to
S288C)
#
source: http://www.indexfungorum.org/names/names.asp

[40]
[40]
[40]
[40]
[40]
[40]
[44]
[44]
[44]
[44]
[45]
-

[46]

Yes

Source of strains: 1L. Kozubowski collection, Clemson University, Clemson, SC, USA;
2
kindly provided by J. Heitman, Duke University, Durham, NC, USA; 3gift from H. de Cock,
Utrecht University, Utrecht, The Netherlands; 4obtained from Westerdijk Institute, Utrecht,
The Netherlands; 5obtained from Euroscarf, Frankfurt, Germany;
Actual taxonomic position: aNaganishia albida; bPapiliotrema aspenensis;
c
Cutaneotrichosporon curvatum; dCryptococcus gattii; ePapiliotrema laurentii;
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f

Cryptococcus neoformans; gPapiliotrema terrestris; hSolicoccozyma terrea; iFilobasidium
uniguttulatum; jMalassezia furfur; kMalassezia sympodialis; lSaccharomyces cerevisiae;
*also known as Cryptococcus albidus var. kuetzingii (Fell & Phaff) Fonseca, Scorzetti &
Fell.

We searched existing databases for sequences of the nuclear ribosomal internal
transcribed spacer (ITS) regions to construct a phylogenetic tree illustrating relatedness
of the species represented by strains tested in our study (Figure 2.1). [47] It should be
underlined that most of the basidiomycetous yeasts tested here represent species more
or less phylogenetically related to the genus Filobasidiella Kwon-Chung (1976) including
the most important species (in the context of the prevalence of cryptococcosis): C.
neoformans and representatives of C. gattii species complex [8]. According to recently
updated taxonomy of Tremellomycetes [40], strains used in this study belong to the
following genera: Cutaneotrichosporon (C. curvatus), Filobasidiella (C. gattii and C.
neoformans), Filobasidium (C. uniguttulatus), Naganishia (C. albidus and C. kuetzingii),
Solicoccozyma (C. terreus), Papiliotrema (C. aspenensis, C. laurentii, and C. terrestris).
While many of the species included here were originally given the name Cryptococcus,
the phylogenetic analysis suggested a significant divergence (Figure 2.1). Thus, our study
included species representing considerably diverse groups among basidiomycetous
yeasts, an important aspect given that occasionally even closely related fungal strains
reveal significant genetic divergence [48].
Assessment of the influence of the temperature on titanization

Three in vitro protocols to induce the formation of bona fide Titan cells in C.
neoformans have been published recently [32] [33] [34]. In all three cases putative Titan
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cells have formed that met established criteria characteristic of cell gigantism observed
originally in vivo during murine infection caused by C. neoformans [26] [27]. While the
titanization protocol developed by Hommel et al. recommended incubation at 30°C, the
methods established by Dambuza et al. and Trevijano-Contador et al. suggested
incubation at 37°C [32] [33] [34]. Therefore, we first analyzed how temperature affected
the growth of the strains included in our study. We reasoned that the ideal temperature
for titanization is close to but not above the maximum temperature a given strain tolerates.
While C. neoformans and C. deuterogattii were capable of proliferating at 37°C, as
reported previously, the majority of non-neoformans/non-gattii species could not grow at
this temperature. Since the majority of these strains could not proliferate at 37°C and
grew at 30°C, we decided to utilize 30°C when testing titanization of these species.
We assessed the ability to form Titan cells based on measurements of the cell
diameter and a visual inspection of cells after incubation under titanization conditions.
Specifically, we defined Titan cells as cells with diameter of close to, or larger than 10
μm, with characteristic central single large vacuole, and a thick cell wall as judged based
on differential interference contrast (DIC) microscopy (Figure 2.2(a)). As we decided to
test Titan cell formation at 30°C, it was important to assess whether lowering the
temperature to 30°C affects titanization in the protocol introduced by Dambuza et al [33].
First, we tested the effect of the temperature on the cell size when C. neoformans (strains
H99 and MD31) and C. deuterogattii (strain R265) were grown in a standard medium
utilized for the growth of C. neoformans (YPD medium) (Figure 2.2(b)). The diameters of
cells of all three strains were no larger than 7 microns at 24 and 30°C. At 37°C, cell
diameters of H99 and MD31 remained under 7 microns and 2% of cells of R265 (two cells
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out of 100 measured) had diameters between 7 and 11 microns. Although for the R265
there was a modest increase in cell diameter between 24°C and either 30 or 37°C, a
change in temperature from 30 to 37°C did not influence cell diameter significantly for any
of the strains. Next, we subjected all three strains to titanization conditions according to
Dambuza et al., at either originally reported 37°C or at 30°C, to test if lowering the
temperature to 30°C had a significant effect on the formation of Titans. Consistent with
previous findings, C. neoformans serotype A strains H99 and MD31, and C. deuterogattii
clinical isolate, strain R265, formed Titan cells after 48 hours of incubation in 10% fetal
bovine serum (FBS) under 5% CO2 at 37°C (Figure 2.2(c)) [32] [33]. Notably for strain
R265, the percentage of Titan cells and the average size of cells were higher at 37°C as
compared to 30°C, in contrast to strains H99 and MD31 for which temperature had a
lesser effect on titanization (Figure 2.2(c)). Furthermore, strain R265 did not proliferate
significantly within 48 hours under titanization conditions, as the number of cells only
increased 3 times at 37°C and 5 times at 30°C, in contrast to C. neoformans H99 and
MD31 for which an increase in cell number was between ~120 and 500 times (Table 1).
Thus, host temperature was not essential for titanization of strains H99, DM31, and R265
(Figure 2.2(c, d)). However, the average size of Titan cells was smaller for R265 strain at
30°C as compared to 37°C suggesting that the temperature of 37°C potentiates this
process in this particular strain (Figure 2.2(c, d)). In contrast, neither H99 nor MD31
exhibited a significant difference in cell diameter between 30 and 37°C under titanization
conditions according to Dambuza et al. These findings confirmed that titanization can
occur at 30°C but 37°C may further stimulate this morphological transition at least in some
species/strains. We also tested titanization at 30°C of additional 6 representative strains
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of the C. gattii species complex (5 strains of C. bacillisporus and 1 strain of C. tetragattii).
Although cells of all 6 tested strains became larger at titanization conditions (indicated in
Figure 2.2(e, f) as #2), as compared to control conditions (indicated in Figure 2.2(e, f) as
#1), the ability to form Titans varied drastically among these isolates (Figure 2.2(e, f)).
Notably, C. bacillisporus strain B4546 exhibited particularly robust titanization with ~81%
of cells (136 out of 167 measured) with diameter above 10 μm and an average diameter
of ~15 μm, contrasting the average cell diameter of the YPD grown B4546 cells (indicated
in Figure 2.2(e, f) as #1) of ~4 μm. Thus, at least some strains of the C. neoformans/C.
gattii species complex are capable of titanization at conditions described by Dambuza et
al. at both 30 and 37°C, although the degree of titanization (percentage of Titans and the
average size of Titans) varies between strains and for some strains is higher at 37 as
compared to 30°C.
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Figure 2. 2 Titan cell formation among the C. neoformans and C. gattii species
complex.
(a) Features of a Titan cell as observed with the DIC microscopy. C. neoformans var.
grubii (strain H99) was grown under titanization conditions according to Dambuza et al.
[33] at 30°C for 5 days. (b) The effect of temperature (24, 30, and 37°C) on cell diameter
of two C. neoformans strains (H99 and MD31) and C. deuterogattii (R265). Cells were
incubated in YPD for 24 hours prior to imaging. (c) The effect of 37°C as compared to
30°C on the median cell diameter under titanization conditions [33] for C. neoformans
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(H99, MD31) and C. deuterogattii (R265). (d) Representative images illustrating cells
incubated at titanization conditions [33] at 30°C, whose diameters are plotted in C. (e)
The effect of incubation under titanization conditions at 30°C for 5 days (marked as #2)
on cell body diameter of C. neoformans (H99) and representative strains of the C. gattii
species complex. Cells were grown in YPD at 30°C for 8 hours as control (marked as #1).
(F) Images of cells whose diameters are plotted in E (#1 – YPD control, #2 – titanization
conditions at 30°C for 5 days). The number of cells counted for each condition were 100
(in b), 110 (;in c), and 167 (in e). The numbers above each plot in C and E represent the
percentage of cells with the diameter above 10 μm. Statistical significance of the mean
cell diameter is indidcated as follows: ns (not significant), ****(p<0.0001). Bars in (a,d)
and (f) represent 10µm.

C. neoformans/C. gattii species complex is unique in the ability to undergo
titanization

Most of the non-neoformans/non-gattii Cryptococcus strains, when subjected to
titanization conditions according to Dambuza et al. [33] with incubation temperature set
at 30°C (indicated in Figure 2.3.1 as #2), have proliferated significantly, as the number of
cells has increased at least 1000 times within 48 hours of incubation (Table 2.2). The
exception was a relatively slower growing C. kuetzingii (130 times increase in cell
number), the two strains of C. uniguttulatus (~9 times, and ~80 times increase), and nearly
completely inhibited C. terreus (Table 2.2). The two Malassezia species grew poorly
under these conditions (~10 times increase in cell number) and S. cerevisiae proliferated
significantly (540 times increase in cell number). Strikingly, after 48 hours at 30°C none
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of the non-neoformans/non-gattii strains formed cells that could be classified as bona fide
Titans according to previously established criteria (Figure 2.3, Table 2.2, and Figure
2.4(a)). We measured cell diameter for selected strains of each species to assess cell
enlargement under titanization conditions. The mean cell diameter of three species, C.
albidus (MD22), M. furfur, and C. terreus was larger at titanization conditions (#2) as
compared to cultures grown in control conditions (#1), although no cells were larger than
10 microns (Figure 2.3,). Interestingly, average cell diameters of three species, C.
aspenensis (DS569), C. laurentii (DS288), and C. terrestris (DS233) were smaller as
compared to those of cells grown in control conditions (Figure 2.3). Average cell
diameters of the remaining four evaluated species were not significantly different
compared to the control (Figure 2.3). We observed morphological differences among the
non-neoformans/non-gattii species under “titanization” conditions according to Dambuza
et al. after 48 h of incubation (Figure 2.3). Most of C. albidus cells, uniquely among other
species, became uniformly round and unbudded and the cells were arranged with spaces
between, indicative of possible capsule formation. C. terrestris and to a lesser extent also
C. aspenensis were the only species that exhibited a large proportion of cells with a single
enlarged vacuole. In four species (C. laurentii, C. terreus, C. uniguttulatus, and S.
cerevisiae) there were a significant number of cells containing multiple vesicles
reminiscent of autophagic bodies. For C. curvatus fragments of pseudohyphae were
observed mixed with elongated budding yeast cells (Figure 2.3). C. terreus exhibited a
highly heterogeneous morphology with some cells being enlarged. These enlarged cells
unlike typical Titan cells, were often not round, lacked single large vacuole, and often
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contained a large daughter cell (Figure 2.3). Such morphology suggested a possible
failure in polarity establishment and a delay in the final cell separation during mitosis.
It was hypothetically possible that some of the non-neoformans/gattii species
required longer incubation time to allow the development of Titan-like cells. To test this
possibility, we also evaluated cell size and morphology after 5-days incubation under
titanization conditions according to Dambuza et al., at 30°C. M. furfur was not included in
this additional analysis. Although the mean cell diameter of C. terreus has further
increased after 5 days of incubation under titanization conditions, no cells were larger
than 10 microns (Figure 2.3 and 2.4). Interestingly, average cell diameter of C. albidus
was smaller after 5 days of incubation in titanization conditions as compared to control,
in contrast to cell enlargement observed after 48 h, even though one cell out of 100 had
a diameter ~ 11 microns (Figure 2.3 and 2.4). No other tested species exhibited cell
enlargement under these prolonged incubation conditions (Figure 2.3 and 2.4). While C.
albidus strain MD22 consisted of mostly unbudded cells, the other strain of this species
(MD41) revealed a heterogeneous population consisting of budding cells (Figure 2.4).
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Figure 2. 3 Members of the Cryptococcus species complex are unique in their
ability to form Titan cells.
C. neoformans (MD31), and representatives of other species, as indicated, were grown
in YPD control medium at 24°C (indicated as #1), subject to the in vitro titanization
protocol established by Dambuza et al. [33] with a modified temperature to 30°C and
incubated for 48 h (indicated as #2) or 5 days (indicated as #3) or subject to conditions
developed by Hommel et al. [34] (indicated as #4). Cell diameters of 100 cells from each
54

condition were measured and plotted. For each strain, representative images are shown
of the cells grown at 24°C in rich YPD medium (#1) or after 48-h incubation in titanization
conditions by Dambuza et el. at 30°C (#2). Statistical significance of the difference in the
mean cell diameter is indicated as follows: ns (not significant), * (0.05 > p < 0.01), ** (0.01
> p < 0.001), *** (0.001 >p< 0.0001), **** (p <0.0001). Bars represent 10µm.

The titanization protocol developed by Trevijano-Contador et al. shares several
aspects with the method introduced by Dambuza et al. [32] [33]. Both protocols require
the use of FBS, and the incubation is performed at 37°C in the presence of 5% CO2. We
initially tested if C. neoformans strain H99 forms robust Titans under conditions according
to Trevijano-Contador et al. with the incubation temperature modified to 28°C and
detected no cell enlargement after 18 hours (data not shown). In contrast to the above
two protocols, the method described by Hommel et al. does not involve FBS, or 5% CO2,
and the cells are incubated at 30°C [34]. In fact, FBS and incubation temperature of 37°C
had a negative impact on titanization as described by Hommel et al. [34]. Furthermore, a
lack of FBS in the method by Hommel et al. reduces the potential for variability associated
with specific batches of the FBS. Therefore, in vitro titanization according to Hommel et
al. constituted an ideal alternative method to be utilized in our study. We selected
representative strains from each species (with the exception of Malassezia) and
subjected these strains to the titanization protocol according to Hommel et al. (indicated
in Figure 2.3, 2.4, and 2.5 as #4) [34]. A representative of C. neoformans (strain MD31)
underwent titanization under these conditions although 5 days of incubation under
conditions by Dambuza et al. has led to more robust titanization as compared to treatment
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according to Hommel et al. (Figure 2.3 and 2.4). The average cell diameter of 5 species
(C. aspenensis, C. curvatus, C. kuetzingii, C. laurentii, C. terrestris) was smaller as
compared to that of the control treatments and no cells with the diameter above 10 μm
were observed (Figure 2.33, 2.4, and 2.5). Cell diameter of C. albidus and S. cerevisiae
was not significantly different when compared to the control treatment (Figure 3). Average
cell diameter of C. terreus was larger as compared to the control treatment, although 98%
of the cells had a diameter of less than 10 microns (two cells out of 100 measuring ~10.5
and ~12.5 μm) (Figure 2.4 and 2.5). Furthermore, similar to the conditions by Dambuza
et al., even the enlarged cells appeared different than typical Titan-like cells observed for
C. neoformans, as no central enlarged vacuole was observed (Figure 2.4). Similarly, C.
uniguttulatus underwent cell enlargement with 99% of the cells measuring no more than
10 μm (1 cell out of 100 had a diameter of ~11 μm) and the cell morphology did not
suggest changes similar to typical titanization (Figure 2.3 and 2.4).

56

Figure 2. 4 Members of the Cryptococcus species complex are unique in their
ability to form Titan cells.
C. neoformans (MD31), and representatives of other species, as indicated, were subject
to the in vitro titanization protocol established by Dambuza et al. (8) with a modified
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temperature to 30°C and incubated for 5 days (indicated as #3) or subject to conditions
developed by Hommel et al. (9) (indicated as #4). Arrows point to cells that underwent
enlargement and are reminiscent of Titan-like cells. Bars represent 10 µm.

Our data suggested that C. terreus, unlike other tested species, undergoes
morphological transition reminiscent of titanization, although the enlarged cells lacked the
characteristic large vacuole. One of the other characteristics of the Titans described in C.
neoformans/C. gattii species complex is an enlargement of the polysaccharide capsule
[32] [34]. We tested if the capsule has formed in any of the species subjected to
titanization protocol according to Hommel et al. [34]. Consistent with previous findings,
Titan cells of the C. neoformans (strain MD31) formed capsules (Figure 2.4(b)).
Interestingly, C. albidus strain MD22 (and to lesser extent strain MD41), and C. terrestris
(strains DS233 and DS290) formed capsules. The remaining species, including the C.
terreus

did

not

reveal

capsule

formation

(Figure

2.4(b)).

In summary, our data suggest that representatives of the C. neoformans/C. gattii
species complex are unique in their ability to form Titan cells when exposed to conditions
described by Dambuza et al. with modified temperature to 30°C or under titanization
conditions described by Hommel et al. [33] [34].

58

Figure 2. 5 Members of the Cryptococcus species complex are unique in their
ability to form Titan cells
A. M. furfur was grown in YPD control medium at 24°C (indicated as #1), or subject to the
in vitro titanization protocol established by Dambuza et al. (8) with a modified temperature
to 30°C and incubated for 48 h (indicated as #2). Indicated other species were subject to
the in vitro titanization protocol established by Dambuza et al. with a modified temperature
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to 30°C and incubated for 5 days (indicated as #3) or subject to conditions developed by
Hommel et al. (9) (indicated as #4). B. Indicated species were stained with nigrosin to
detect capsule formation. Bars represent 10 µm.

II.4 Discussion

The aim of this study was to assess the ability to titanize among various non-C.
neoformans/non-C. gattii yeast species. We utilized two in vitro titanization protocols
described recently by Dambuza et al. and Hommel et al. [33] [34]. Knowing that
representatives of C. neoformans and C. gattii species complex are unique within the
order Tremellales for their ability to grow at a temperature above 30°C [49] and based on
our tests (Table 2.1f) it was necessary to slightly modify the protocol developed by
Dambuza et al. by changing the incubation temperature from 37°C to 30°C. Consistent
with previous findings [32] [34], we demonstrated that C. neoformans strain H99 and at
least 4 out of 7 strains of the C. gattii species complex were able to form Titan cells at
30°C in the presence of 5% CO2. Interestingly, C. bacillisporus strain B4546 exhibited
particularly robust titanization. Hommel et al., have demonstrated that a truncated PKR1
allele is associated with an increase in titanization [34]. It would be of interest to explore
whether specific changes in gene expression and activity related to PKR1 have led to
increased titanization of the strain B4546. Dambuza et al. reported a lack of titanization
in the C. deuterogattii strain R265 suggesting that perhaps under their specific conditions
this strain is not stimulated to form Titan cells [33]. This was not the case in our study, as
the R265 strain and at least 3 out of the remaining 6 strains of the C. gattii species
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complex tested here formed Titan cells under conditions similar to those utilized by
Dambuza et al.
Our results clearly show that under in vitro conditions examined here neither of
the evaluated 21 strains of non-C. neoformans/non-C. gattii Cryptococcus species is able
to form bona fide Titan cells (Figure 2.3; Table 2.1, Figures 2.4, 2.5) as defined by two of
the adopted criteria, namely cell body diameter of more than 10 μm and a large centrally
positioned vacuole [33]. Changes at the micromorphology level were observed in the case
of both tested strains of C. curvatus. While cultures incubated in YPD medium at 24°C
consisted of only single, elongated budding cells, in the presence of 10% FBS in PBS,
mycelial growth similar to species belonging to Trichosporon genus [50] were observed
(Figure 3), to which C. curvatus is phylogenetically related [51]. Notably our results are
consistent with the phylogenetic relatedness among tested species. Particularly striking
were similar results obtained for C. aspenensis, C. laurentii, and C. terrestris, with all
three species exhibiting a reduction in cell body diameter in titanization conditions. C.
terreus, represented by one strain in our study, was an exception as we found occasional
cells that were relatively larger than the rest of the population with the appearance
reminiscent of the Titan-like cells. While these cells did not possess a large vacuole and
were not larger than 12 μm, our findings suggest that C. terreus may also undergo
morphological transition similar to titanization under specific conditions. Importantly, no
capsule was detected even in enlarged cells of C. terreus under conditions by Hommel
et al. [34], suggesting a lack of typical titanization. A lack of capsule in C. terreus was
inconsistent with previous studies in this species, perhaps due to differences in the
experimental approach [52]. C. uniguttulatus also revealed occasional enlarged cells
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under titanization conditions (Figure 2.4). However, in contrast to C. terreus most of these
cells were not round and were indicative of failure in cell polarity and/or cell separation
(Figure 2.4). Future studies should evaluate other characteristics associated with
titanization in C. terreus, C. uniguttulatus, and other species tested here. While the strains
tested in our study represent various groups within basidiomycetous yeasts, it is still
possible that other species may be capable of titanization. For instance, more closely
related Cryptococcus species sensu stricto, C. amylolentus may be able to titanize.
Unfortunately, a limited number of isolates of this species is available, which undermines
the significance of this potential test [53]. Additionally, it is plausible that some or all of the
species tested in this study are capable of morphogenetic transition to form Titan-like cells
but they may require specific environmental cue(s) not tested here. While this alternative
remains a possibility, we would like to note that the formation of true hyphae, another
morphological transition, is not common to all yeasts. Moreover, while Candida albicans
forms enlarged “Goliath” cells in response to zinc limitation, this morphological transition
is not conserved in other Candida spp., Clavispora lusitaniae, and Debaryomyces
hansenii and Goliath cells are not morphologically similar to Titan cells [54].
The uniqueness of C. neoformans/C. gattii species complex for titanization under
specific conditions described here emphasizes the success of these species to evolve as
human pathogens. Future studies should reveal if other environmental cues exist to
induce various yeast species to form Titan-like cells possessing all the characteristics
described for Cryptococcus species complex. Several genes were recently described as
implicated in titanization of C. neoformans [32] [34]. It would be of interest to establish if
these genes are conserved in species tested here, for instance in C. terreus, and other

62

species outside of the Cryptococcus species complex. The growing number of sequenced
fungal genomes, including the genomes of species belonging to the order Tremellales,
will certainly augment studies towards elucidating the genetic basis of titanization.
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III.1 Abstract

Opportunistic pathogens of the anamorphic genus Cryptococcus are unique
considering their virulence factors that in the context of pathogenesis allowed them to
achieve evolutionary success. Morphological transformation into giant (Titan) cells is
one of the factors contributing to cryptococcosis. Recently established in vitro protocols
demonstrate that 5 or 10% fetal bovine serum (FBS) combined with 5% CO2, 37˚C, and
sufficiently low cell density, triggers cellular enlargement (Serum protocols). However,
the FBS components that promote this morphological transition remain incompletely
characterized. In search of minimal conditions necessary for stimulating the formation of
Titan cells, we performed a study where we eliminated serum from the protocol (Serumfree protocol) and instead systematically adjusted the amount of glucose, source of
nitrogen (ammonium sulfate), and the pH. We found that exposing cells to PBS with
adjusted pH to 7.3, and supplemented with 0.05% glucose, 0.025% ammonium sulfate,
0.004% K2HPO4, 0.0035% MgSO4, in the presence of 5% CO2 at 37˚C triggers Titanlike cell formation to the same degree as the previously established protocol that utilized
10% FBS as the sole nutrient source. Titan-like cells obtained according to this Serumfree protocol were characterized by cell body size over ten microns, a single enlarged
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vacuole, thick cell wall, extensive polysaccharide capsule, and changes in the level of cell
ploidy, all currently known hallmarks of Titan cells found in vivo. Strikingly, we found that
in both, Serum and Serum-free protocols, an optimal pH for Titan-like cell development
is ~7.3 whereas relatively acidic pH (5.5) prevents this morphological transition and
promotes robust proliferation, while alkaline pH (~8.0) has a profound growth inhibitory
effect. Our study demonstrates a critical role of pH response to the formation of Titan cells
and indicates that conditions that allow restricted proliferation in the presence of 5% CO2
are sufficient for this morphological transition to form enlarged cells in Cryptococcus
neoformans and Cryptococcus gattii species complex

III.2 INTRODUCTION

Species belonging to the Cryptococcus neoformans and Cryptococcus gattii
complex are one of the most important etiological agents of invasive fungal infections
(IFIs) accompanied by high mortality [1,2]. Almost one million cases of cryptococcal
infections of the central nervous system (CNS) occur every year resulting in more than
600,000 deaths including 15–17% of AIDS-related deaths worldwide [3,4]. While
members of the C. neoformans species complex can cause mostly opportunistic
infections in immunocompromised individuals, representatives of the C. gattii species
complex are able to also infect immunocompetent persons [5–8].
Members of the C. neoformans/C. gattii species complex are able to undergo
morphological transition and form enlarged cells termed Titan cells, which have been
shown to enhance dissemination and persistence in the host [9,10]. When grown in vitro
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in rich media, the diameter of the cells of C. neoformans/C. gattii species complex is within
the range from 4 to 6 µm. In contrast, Titan cells are larger than 10 µm, possess a thicker
cell wall due to the additional layer of chitin, single centrally located large vacuole, and
single nucleus characterized by increased ploidy [11–13]. Titan cells are also more
resistant to phagocytosis [9,11,14,15] and aneuploid daughter cells of C. neoformans
Titan cells show increased resistance to environmental stress, including exposure to
antifungal drugs [10]. The role of Titan cells in pathogenesis is unclear, as some studies
show Titan cell production impacts virulence in animal models, but this impact in human
studies is less clear because strains that do not form Titan-like cells in vitro have been
isolated from humans [16–19]. Nonetheless, the recent study suggests that the formation
of Titan cells is unique to pathogenic Cryptococcus species, as a similar morphological
transition has not been detected in vitro in several species that do not belong to the C.
neoformans and C. gattii species complexes [20].
External physicochemical factors that stimulate the formation of Titan-like cells and
genes that are crucial for the development of Titans are not fully established [16–18].
Pathways shown to be involved in this process include the cyclic adenosine
monophosphate (cAMP) signaling (dependent on the transcription factor Rim101) and the
mating pathway [13,21,22]. Critical for our understanding of the mechanisms of triggering
the formation of Titan cells are recently established protocols that allow obtaining Titanlike cells in vitro [16–18]. These studies indicated that Titan cell formation can be
stimulated or is dependent on different external signals like CO2, hypoxia, and incubation
in the presence of fetal bovine serum (FBS) [16–18]. Among constituents of the FBS,
phospholipids, and bacterial cell wall components were shown to stimulate cellular
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enlargement [16,18,23]. Consistently, Titan-like cells have been observed in C.
neoformans grown in YNB (yeast nitrogen base medium) when co-cultured with bacteria
[18]. However, Titan-like cells have been also obtained under conditions of continual fourday incubation of C. neoformans in YNB medium alone, although Titan-like cells obtained
under these conditions reached sizes that were relatively smaller as compared to Titan
cells obtained in vivo [11]. Furthermore, a recent study indicates that transition to Titan
cells is stimulated by the G2 cell cycle arrest followed by a return to the cell cycle with
reduced expression of the cyclin gene CLN1 [24].
Based on these studies, we hypothesized that optimal for the formation of Titanlike cells in vitro are conditions that sufficiently restrict proliferation in the presence of 5%
CO2. To validate this hypothesis, we systematically tested representative members of the
C. neoformans/C. gattii species complex for their ability to undergo this unique
morphological transformation when cells are brought from poor-nutrient media to fresh
PBS-based media with decreasing levels of nutrients at various pH values in the presence
of 5% CO2 at 37 °C. We found an optimal level of nutrients and the pH that allow the
formation of Titan-like cells to the same extent as the recently established protocol that
required the addition of the FBS. Our data indicate that minimal conditions sufficient to
trigger the development of Titan-like cells in vitro include 5% CO2, 37°C, pH of ~7.3, and
the amount of glucose and source of nitrogen below a specific threshold.
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III.3 Materials and Methods

Tested Strains and Media

All the tested strains utilized in this study are listed in Table 2. Strains were cultured
on YPD (Yeast extract Peptone Dextrose) semisolid medium, followed by liquid YPD
medium: 1% yeast extract, 2% bacto-peptone, and in case of semisolid media 2% bacto
agar (BD Difco, Sparks, MD, USA, cat. no. REF212720, REF211820, and REF212720)
and filter-sterilized 2% glucose (VWR International LLC, West Chester, PA, USA, cat. no.
BDH0230). For the Titan induction experiment, cells were routinely grown overnight in 5
mL YNB (Yeast Nitrogen Base) liquid medium: 0.67% Yeast Nitrogen Base with amino
acids, pH 5.5 (Sigma cat. no. Y1250, St. Louis, MO, USA), 2% glucose with horizontal
shaking at 220 rpm and with incubation at 30°C (Thermo Scientific, MAXQ4450).
In Vitro Titan Cells Induction

Titan cells were obtained in vitro according to recently described protocols [17,18].
To follow the protocol established by Dambuza et al. [18], experiments were performed
in sterile, biologically active 10% Fetal Bovine serum (FBS, Sigma, cat. no. F6178) diluted
by 1x concentrated PBS (Dulbecco`s Phosphate Buffered Saline w/o Ca2+ and Mg2+, cat.
no. REF21-031-CV, Corning cellgro®, Manassas, VA, USA), at final pH established on
the level 7.4. Original concentrated FBS was normally stored in 2.5 mL aliquots at −20 °C
to avoid repeated freeze-thaw procedure. Cryptococcal cells were incubated in static
conditions for 48 h at 37°C and under 5% CO2 atmosphere (New Brunswick an Eppendorf
company, Galaxy 170S, Ayrshire, Scotland). To follow the protocol established by
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Hommel et al. [17], cells at final concentration 107 cells/mL were initially incubated in 10
mL of the YPD liquid medium in flat bottle flasks at 30 °C with horizontal shaking at 150
rpm (Thermo Scientific, MAXQ4450) for 22 h. Next, cultures were centrifuged (5 min,
3000× g rpm, room temperature) and the cells were washed twice using sterile MM
medium: 15 mM D-glucose, 10 mM MgSO4, 29.4 mM KH2PO4, 13 mM Glycine and 3.0
µM Thiamine (Sigma cat. no. G8270, M7506, P5655, G7126 and T4625, respectively). In
the final stage, cells were resuspended in 1 mL of MM medium in 1.5 mL Eppendorf tubes
to obtain density equal to 106 cells/mL (calculations performed based on cell counting
using hemocytometer). Cells were incubated simultaneously in MM medium with pH
established on the level 4.5, 5.5, 7.3 and 8.0. Cell suspensions prepared in this way were
incubated for up to 5 days at 30°C with horizontal shaking at 800 rpm (Eppendorf
ThermoMixer, Eppendorf, Enfield, CT, USA). For the optimized Serum-free protocol,
experiments were performed according to the protocol by Dambuza et al. [18] except that
10% FBS was replaced by low nutrient medium (0.025% ammonium sulfate, 0.05%
glucose, 0.007% K2HPO4 and 0.008% MgSO4) and pH was adjusted to 7.3. To obtain
these optimal conditions, initially the influence of different pH and various concentrations
of components of the mentioned low nutrient medium (glucose and ammonium sulfate)
were evaluated in a checkerboard-like assay in sterile 12-well microtiter plates (VWR®,
USA), following the standard protocol [27].
Evaluation of Cell Viability

Each time viability of cells was routinely evaluated qualitatively by examination of
micro-wells of the titration plate directly under the light microscope and quantitatively by
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plating on YPD medium. For this purpose, after mixing the contents of each micro-well of
the titration plate, 100 µL volume was collected and either initially diluted (if necessary)
using sterile 1x concentrated PBS or directly spread on YPD semi-solid medium. Plates
were routinely incubated for 48 h at 30°C in the incubator w/o CO2 (Thermo Scientific,
Heratherm Incubator IMH180, Langenselbold, Germany). After this time, plates were
photographed, and colony counting was performed both to assess viability of cells as well
as to determine total number of cells after the terminal point of the experiment.
Negative Staining with India Ink

Capsule visualization was performed based on negative acidic staining method
with India ink. This technique permits visualization of the transparent and unstainable
capsule in case of Cryptococcus spp. [28]. For this purpose, microscopic preparations
were performed as follows, 5 µL of India ink solution and 5 µL of yeast liquid culture was
mixed on the surface of microscopic slide and then covered with a cover glass. All the
microscopic preparations were examined using immersion oil and 100x objective under
light microscopy using Leica DMi8 inverted microscope (Leica Microsystems Inc, Buffalo
Grove, IL, USA).
Flow Cytometry to Determine Ploidy of Cells

Cell suspension obtained from the experiment to induce Titan cells was transferred
into a 2 mL microfuge tube at a final concentration of cells equal to ~105 cells/mL. Cells
were harvested by centrifugation (30 s, 13,000× g at ~25°C). Supernatants were
removed and cells were resuspended in 1 mL 70% ethyl alcohol (EtOH). Cells were then
incubated at ~25°C for 1 h and transferred to 4°C overnight. The next day, cells were
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centrifuged for 1 min and supernatant was removed. Cell pellets were briefly washed with
1 mL citrate solution (0.017% citric acid, 1.44% sodium citrate, Sigma cat no. 251275 and
PHR1416, respectively), pH 7.0, and resuspended in 1 mL of freshly prepared citrate
solution with RNase A (0.25 mg/mL, Sigma cat. no. R4875) and SYTOX® Green (500
nM, Invitrogen cat. no. S7020). Samples were covered with aluminum foil and left at 4°C
overnight. The next day immediately before analysis, cells were sonicated at an amplitude
of 20% for ~10 s to avoid clumping and analyzed via fluorescence flow cytometry. For
ploidy analysis, SYTOX® Green fluorescence data were collected from 10,000 cells on a
Beckman Coulter Cytoflex flow cytometer using the 488 nm blue laser with emission in
the 530/30 BP filter. For the DNA content analysis based on propidium iodide (PI) staining,
cells were fixed with EtOH for 24 h followed by staining using PI solution (5 µg/mL) with
constant shaking at room temperature for 40 min. PI was removed by 1 min centrifugation
at 5000 rpm and the cells were left overnight at 4°C in PBS.
Microscopy and Imaging

All the microscopic observations were performed using inverted microscope (Leica
DMi8, Leica Microsystems Inc, Buffalo Grove, IL, USA) using a 20x, 40x or 100x
objectives and built-in camera for photographic documentation. Photographs were
analyzed using Leica Application Suite X (LAS X) software (Leica Microsystems Inc,
Buffalo Grove, IL, USA). For the assessment of cell body diameter, at least 150 cells for
each treatment were measured using ImageJ (https://imagej.nih.gov/ij/). The data were
visualized using the GraphPad Prism v. 8 software (San Diego, CA, USA).
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Spot Test Assay

To assess the susceptibility to different pH values in the case of the selected
Cryptococcus sp. strains and to compare the relative susceptibility of several strains, the
cells were grown to mid-log phase, diluted to OD600 ≈ 0.25 and spotted (3 μL) in 10-fold
serial dilutions (100, 10−1, 10−2 and 10−3) onto the YPD plates with different pH. Plates
were incubated at 30°C and photographed after 72 h or 96 h, depending when the
phenotypic effect was most visible. The susceptibility assays were repeated a minimum
of two times. Differences in growth show variability of the tested strains in their
susceptibility to pH [29].
Statistical Analysis

To test differences between the median of total cell body (cell body with the
capsule) or cell body, or the capsule (total cell body diameter minus cell body diameter
and divided by 2) diameter, first the Normality Kolmogorov-Smirnov test was performed
and subsequently, the one-way ANOVA (for normally distributed data) or Mann–Whitney
and Kluskal–Wallis tests (non-parametric) were performed with the use of GraphPad
Prism v. 8 software (San Diego, CA, USA).

III.4 Results

A Critical Role of the pH in the Formation of Titan Cells

A recent study suggested that the members of the C. neoformans/C. gattii species
complex, among the other basidiomycetous yeasts, are uniquely capable of forming Titan
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cells, but the basis for this presumed distinct characteristic remains unclear [20]. The
Rim101 transcription factor, which is involved in the cellular response to changes in pH,
has been implicated in the formation of Titan cells [25]. A recent study has demonstrated
the influence of the pH on the formation of Titan-like cells in vitro based on a protocol that
involved exposing stationary phase cells of C. neoformans to conditions with limited
aeration [17]. To evaluate the potential correlation between response to pH and the ability
to form giant cells, we tested 8 non-neoformans/non-gattii basidiomycetous species for
their sensitivity towards pH. We noted that four strains (representing three species) of the
C. neoformans/C. gattii species complex were relatively more sensitive to alkaline pH as
compared to 11 strains (representing 6 species) of non-neoformans/non-gattii
Cryptococcus species (Figure 3.1A). This observation that the species sensitive to high
pH are the species that form Titan cells led us to test the impact of pH on in vitro Titanlike cell production. We modified the protocol developed by Dambuza et al. that induces
Titan cell formation using fetal bovine serum (FBS) to include exposing cells to various
pH levels [18]. We found that pH significantly influenced Titan-like cell formation after 48
h of incubation of two representative members of the C. neoformans and C. gattii species
complexes (Figure 3.1B). Specifically, at pH 5.5, no Titan-like cells were formed and the
cultures proliferated abundantly. At pH 7.0, proliferation was still relatively high, and no
Titan-like cells were obtained. Strikingly, at pH~7.3, less proliferation was observed, and
Titan-like cells were formed. Increasing the pH to ~8.0 resulted in drastic inhibition of
growth and a lack of cellular enlargement (Figure 3.1B). Finally, we also investigated how
initial inoculum size affects the pH of culture after 48 h incubation and the total number of
cells under conditions based on the Dambuza et al. protocol [18]. After 48 h of incubation
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in case of the initial inoculum established on the level of 104 cells/mL, we could find
significantly greater differences between the pH values respectively for time T0 and T48,
indicating faster and more pronounced acidification of the medium compared to the
results obtained for the initial inoculum equal to 103 cells/mL (Table 3.1). Among the four
strains tested of the C. neoformans/C. gattii species complex, only the C. bacillisporus
B4546 strain achieved a much lower density (defined as the number of cells per milliliter)
and acidified the culture to a much lesser extent (10% FBS in PBS). This suggests that
this strain is more sensitive to even slightly alkaline pH (~7.2) and proliferates particularly
well at acidic pH. Moreover, strain B4546 under such conditions is able to form Titan cells
with high efficiency, as has been demonstrated previously [20]. The size of the initial
inoculum also influenced the efficiency of the Titan cell formation, namely the percentage
of Titans was smaller when starting inoculum was equal to 104 cells/mL as compared to
103 cells/mL (Table 3.1).
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Figure 3. 1 The effect of pH and nutrient level on the formation of Titan cells
(A) A spot test assay was utilized to test the sensitivity to alkaline pH of representative
strains (alternative strains of the same species are indicated by numbers and are
characterized in detail in Table 2) of the non-neoformans and non-gattii species as
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compared to four representative strains (underlined) of the C. neoformans/C. gattii
species complex. Experiments based on spot test assay were performed in two
independent repetitions. (B) The level of pH is critical for the formation of Titan-like
cells in C. neoformans (H99) and C. deuterogattii (R265) in a modified “Serum”
protocol based on a method developed by Dambuza I.M. et al. [18]. (C) The level of
pH (4.5, 5.5, 7.3, and 8.0) influences the percentage of Titan cells obtained in a
modified protocol based on the method established by Hommel B. et al. [17]. The
formation of Titan-like cells was tested for two representatives of the C. neoformans
(strains MD31 and H99), and at least 200 cells were measured for each sample. Differences in cell body diameter between the experimental groups were significant
(one-way ANOVA, p = 0.001). (D) Optimal conditions for the development of Titanlike cells were established in a Serum-free protocol. A method developed by
Dambuza I.M. et al. has been modified such that the fetal bovine serum (FBS) has
been replaced by various levels of nutrients (ammonium sulfate: AS, glucose: G) and
pH levels (5.5, 7.3, 8.0), as indicated (see text for more details). Results are shown
for C. deuterogattii strain R265 and C. neoformans strain MD31. For each strain and
condition, at least 200 cells were measured. Above the plot, for each sample, the
percentage of Titan cells (cell body diameter above 10 microns) is indicated. For each
of the four versions of the nutrient content, the median cell body diameter at pH = 7.3
was significantly different from the diameter of cells incubated at pH 5.5 or 8.0
(Kruskal-Wallis test, p = 0.001). Scale bars are 20 microns in B and 10 microns in
C.neoformans
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Table 3. 1 Cell density, pH values and percent (%) of Titan cell after 48h of
incubation according to conditions described by Dambuza et al. (18) depending
on initial incoculum and tested strains of the Cryptococcus
neoformans/Cryptococcus gattii species complex

Figure 3. 2 Strains used in this study, their source, place of the first isolation and
the newest taxonomic position #.
# Internet source: http://www.indexfungorum.org/names/names.asp.
Strain
Cryptococcus albidus a, MD22.
1

Cryptococcus aspenensis b, DS570
2
Cryptococcus aspenensis b, DS569
Cryptococcus curvatus c, MD120/2009
C. deuterogattii d R265 (CBS10514)
Cryptococcus bacillisporus WM161
Cryptococcus bacillisporus B4546
Cryptococcus bacillisporus NIH312
Cryptococcus kuetzingii a,*
MUCL27749
1
Cryptococcus laurentii e, DS619
2
Cryptococcus laurentii e, DS288
1
Cryptococcus neoformans f H99
2
Cryptococcus neoformans f MD31
1

Cryptococcus terrestris g, DS291
2
Cryptococcus terrestris g, DS233
3
Cryptococcus terrestris g, DS234
4
Cryptococcus terrestris g, DS290
Cryptococcus terreus h, DUMC177.8
1

Cryptococcus uniguttulatus i, MD29

Source (1−3), Primary Isolation
I
Interdigital spaces of the feet, component of the
skin
mycobiome (healthy male, Poland)
II
Populus tremuloides, New York State (USA)
II
Populus tremuloides, New York State (USA)
I
Soil, Olsztyn, Poland
III
Bronchial washings of infected patient from the
Vancouver
Island, British Columbia, Canada, VGIIa genotype
II
Environmental isolate, San Diego CA, USA, VGIIIa
genotype
II
VGIIb genotype
II
Clinical isolate from cerebrospinal fluid, VGIIIb genotype
II
Intestinal tract, Blatta orientalis
II

Picea abies, New York State (USA)
Colophospermum mopane, Botswana
II
Male patient with Hodgkin’s disease, New York, USA
I
Bronchoalveolar lavage (BAL) of patient with AIDS,
Poland
II
Colophospermum mopane, Botswana
II
Colophospermum mopane, Botswana
II
Colophospermum mopane, Botswana
II
Colophospermum mopane, Botswana
II
Soil, New Zealand
I
Interdigital spaces of the feet, mycobiome (healthy
female,
II
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Poland)
2

Cryptococcus uniguttulatus i, MD26

I

Soil, Wroclaw, Poland
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Source of strains: I L. Kozubowski collection, Clemson University, Clemson, SC, USA; II
kindly provided by J. Heitman, Duke University, Durham, NC, USA; III gift from H. de
Cock, Utrecht University, Utrecht, The Netherlands; 1–4 Roman numerals in superscript
are compatible with those indicated in Figure 3.1A; Actual taxonomic position: a
Naganishia albida; b Papiliotrema aspenensis; c Cutaneotrichosporon curvatum; d
Cryptococcus gattii; e Papiliotrema laurentii; f Cryptococcus neoformans; g Papiliotrema
terrestris; h Solicoccozyma terrea; i Filobasidium uniguttulatum; * also known as Cryptococcus albidus var. kuetzingii (Fell & Phaff) Fonseca, Scorzetti & Fell.

85

86

Figure 3. 3 A direct comparison of the percentage of Titan cells obtained in an
optimized Serum-free protocol (Low nutr., 0.025% ammonium sulfate, 0.05%
glucose) as compared to the method developed by Dambuza I.M. et al. (FBS) [18].
(A) C. neoformans strain MD31 and C. deuterogattii strain R265 were utilized. As controls,
cultures grown in a rich YPD medium at logarithmic (Log. Phase, shown in A and C) or
stationary phase (Stat. phase, shown in A) of growth were evaluated. For each sample,
the cell/capsule diameter for at least 150 cells was measured. Star indicates statistical
significance (p = 0.001). (B) Cells evaluated in A were stained with India ink to visualize
the capsule. (C) Nuclei of cells evaluated in A were stained with SYTOX® Green and
fluorescence flow cytometry was performed to examine ploidy. The Y-axis scale was
adjusted in each panel to facilitate the comparison of peaks for each sample. The scale
bar in B represents 10 microns.
An alternative in vitro protocol to obtain Titan-like cells has been established that
does not include exposure to FBS and 5% CO2 [17]. In this protocol, established by
Hommel B. et al., cellular enlargement occurs when stationary phase cells are exposed
to conditions with restricted aeration at 30°C [17]. Evaluating four levels of pH in this
protocol (4.5, 5.5, 7.3, and 8.0) revealed that C. neoformans (H99 and MD31) did not
form Titan-like cells at pH 5.5 and the highest percentage of Titan-like cells was obtained
at extreme pH (4.5 and 8.0) (Figure 3.1C). At pH 7.3, the C. neoformans strain H99 did
not form Titan-like cells, whereas the C. neoformans strain MD31 underwent this
transition (Figure 3.1C). Interestingly, when using the protocol established by Hommel B.
et al., no cellular enlargement was observed in the case of four representatives of the C.
gattii species complex (C. bacillisporus strains WM161, B4546, NIH312 and C.
87

deuterogattii strain R265) under the four levels of pH tested (data not shown). Thus, pH
plays a critical role during the formation of Titan-like cells in vitro and the optimal pH level
differs between conditions that include 10% FBS and 5% CO2 [18] and those that expose
the cells to hypoxia-like conditions [17]. Furthermore, a relatively high level of sensitivity
to alkaline pH may be contributing to the unique ability of the members of the C.
neoformans and C. gattii species complexes to form Titan cells.
Establishing Optimal Conditions to Obtain Titan-like Cells In Vitro

A common factor between the two established in vitro protocols that included the
FBS [16,18] seems to be the transfer of cells to the culture media that limit robust
proliferation [11,26]. It is commonly known that serum can induce capsule growth [26] but
also cellular enlargement [16,18]. Moreover, serum is most effective in inducing
enlargement under nutrient-limited media [26]. This presumed limitation of proliferation
may be due to relatively low nutrient content of the FBS and/or some specific FBS
components that exhibit an inhibitory effect on growth and/or due to suboptimal pH. We
hypothesized that replacing FBS by defined nutrient composition at levels sufficiently low
to restrict proliferation may trigger cellular enlargement. To test this possibility, we
modified the protocol established by Dambuza I.M. et al. [18], by eliminating the FBS and
instead supplementing phosphate-buffered saline (PBS, which was originally included in
the protocol) with glucose and a nitrogen source (ammonium sulfate) at decreasing four
concentrations (Serum-free conditions). We also established that it was necessary to
supplement the medium with inorganic magnesium and phosphate (0.007% K2HPO4 and
0.008% MgSO4), otherwise, there was no proliferation observed (data not shown).
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Importantly, we tested three levels of pH for each of the nutrient levels. This
“checkerboard” type of assay led to the identification of optimal conditions for the
formation of Titan-like cells with respect to pH and nutrient content (Figure 3.1D).
Specifically, we found that adjusting the PBS to a pH of ~7.3, and adding 0.05% glucose,
0.025% ammonium sulfate, 0.007% K2HPO4, and 0.008% MgSO4, in the presence of 5%
CO2 at 37°C results in conditions that trigger Titan-like cell formation to the highest levels
(Figure 3.1D). These conditions were optimal for two strains, namely C. neoformans
MD31 and C. deuterogattii R265 (Figure 3.1D). This result suggested that FBS is not a
necessary component to trigger the formation of Titan-like cells at 37°C in the presence
of 5% CO2. However, it remained possible that FBS could have an effect that stimulates
this morphological transition to a larger extent than the optimal conditions established
here. To test this possibility, we evaluated two strains: C. neoformans strain MD31, and
C. deuterogattii strain R265, for their ability to develop into Titan-like cells under Serum
(a protocol according to Dambuza I.M. et al. [18]) and the optimal Serum-free conditions
established here (Figure 3.2A, B). Strikingly, for both species, Titan-like cells were
induced to a similar extent in both protocols (Figure 3.2A,B). Importantly, both protocols
led to Titan-like cells characterized by cell body diameter above 10 µm, enlarged central
vacuole, thick cell wall, enlarged capsule (Figure 3.2A,B), and changes in the level of cell
ploidy (Figure 3.2C), all hallmark features of Titan cells found in vivo. For cells subject to
both protocols for 48 h, DNA content was estimated based on staining with the SYTOX®
Green stain (Figure 3.2C). In addition, cells were subject to Serum-free protocol for 5
days and DNA content was estimated based on SYTOX® Green and propidium iodide
staining for comparison (Figure 3.3). This alternative staining method further confirmed
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an increase in DNA content when cells were subject to the Serum-free protocol (Figure
3.3). Interestingly, an average capsule thickness was higher in C. deuterogattii R265 cells
as compared to C. neoformans MD31 when the cells were treated by either of the two
protocols, which has contributed to an overall larger total cell diameter in R265 as
compared to strain MD31 (Figure 3.2 A,B). In addition, when the Serum-free protocol was
further modified by changing the initial incubation from YNB (poor nutrient) medium to
YPD (nutrient-rich medium), no Titans were formed, a result similar to that obtained in the
previously established Serum protocol [18] (data not shown).
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Figure 3. 4 Analysis of the DNA content in cells grown in YNB medium (control,
blue) or cells subject to Serum-free protocol (red).
Cells were stained for DNA content with either SYTOX® Green or propidium iodide.
Yellow indicates additional control of cells that were not stained for the DNA content. The
analysis was performed for C. neoformans MD31 and C. deuterogattii R265 strains. The
percentage of the population was normalized to mode.

III.5 Discussion

Collectively, our results clearly indicate that the formation of Titan-like cells can be
triggered in vitro when cultures are brought from poor nutrient media (YNB) to conditions
that restrict robust proliferation. For instance, this can occur when cells are exposed to
sufficiently low nutrients at a pH that is not optimal for proliferation under 5% CO2 at 37°C,
or when cells are exposed to hypoxia-like conditions. While previous studies have
provided compelling evidence that specific component/s in the FBS can stimulate the
development of Titan-like cells, our data indicate that FBS is not essential for this
morphological transition if cells are brought from poor nutrient media at sufficiently low
density to fresh media that contain the number of nutrients that is sufficiently low to limit
proliferation, the pH is ~7.3, and the incubation is under 5% CO2 at 37°C.
Two striking aspects are commonly observed when the formation of Titan-like cells
is triggered in vitro. First, typically, a relatively small fraction of the cell population
undergoes this morphological transition. Zaragoza O. et al. provided compelling evidence
that mostly old cells in the population are those that undergo cellular enlargement, which
may explain a small fraction of Titan-like cells often reported in other studies [11]. Second,
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it has been reported that the percentage of Titan-like cells formed in vitro varies
significantly depending on a specific strain. For instance, over 80% of the population of
C. bacillisporus strain B4546 exhibited this morphological transition in vitro according to
Serum protocol [20]. On the other hand, the same strain failed to exhibit cellular
enlargement under modified Serum-free conditions presented here (data not shown).
These findings suggest that to form Titan cells, the population must be exposed to
conditions that restrict robust proliferation, which would depend on incubation conditions
and the type of cells/strains. Considering recent findings pointing to a critical role of cyclin
Cln1 in the formation of Titan cells [24], it is possible that a “potency” to re-enter the cell
cycle, dependent on the levels of the cyclins, determines whether a cell enters a route to
become a Titan. Accordingly, old cells in the population would have a low potential to
proliferate upon cell cycle re-entry. In addition, cell physiological factors that determine
the formation of Titan cells are likely multifactorial. For instance, a formation of a large
vacuole may play an important role in this process. In support of this possibility, we
observe that the C. bacillisporus strain B4546 exhibits a large proportion of cells with
enlarged central vacuoles already during the initial incubation in the YNB medium, a stage
when no enlarged cells (over 10 µm size) are yet formed, which contrasts with other
strains tested that show no large vacuoles at this initial stage of the protocol (data not
shown). The potential role of the formation of large vacuoles is consistent with the
influence of the pH. Furthermore, it has been demonstrated that formation of Titan-like
cells in vitro in the presence of the FBS requires sufficiently low cell density [16]. Similarly,
both for Serum-protocol [18] as well for the Serum-free protocol we observed that each
of the two mentioned re-quires a cell density of ~1000 cells/mL to effectively lead to
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cellular enlargement (Table 1). It has been suggested that quorum sensing is important
for the formation of Titans [17]. However, a non-exclusive alternative explanation of this
relationship could be that at higher densities, cells can acidify the medium to the degree
sufficient to stimulate proliferation and prevent cellular enlargement. This conclusion is
supported by the results obtained in the experiment performed according to the protocol
established by Dambuza et al. [18]. Our data indicate that a higher density of initial
inoculum, i.e., 104 cells/mL resulted in a lower pH of the culture and a lower percentage
of Titans after 48 h as compared to initial inoculum size equal to 103 cells/mL (Table 1).
Data from this study suggest that the members of the C. gattii species complex do
not form Titan-like cells under conditions previously established by Hommel B. et al. [17].
This result suggests that in contrast to older cells in the population of the C. neoformans,
cells of the members of the C. gattii species complex proliferate upon re-entry of the cell
cycle at a higher rate when exposed to hypoxia-like conditions, which may prevent those
cells from entering a path to develop into Titan-like cells. This hypothesis is also based
on the results obtained by Altamirano et al. [24], however, a study that compares the
ability to re-enter the cell cycle between those species will be needed to test this
possibility.
The uniqueness of members of the C. neoformans/C. gattii species complex to
form Titan-like cells under established conditions described previously [20] emphasizes
the evolutionary success of these fungi to develop as human pathogens. Our results
suggest that what accounts for the ability to form Titan cells is increased sensitivity to
alkaline pH. Given that the host internal body's physiological pH is ~7.3, and the lung
environment is deprived of nutrients available for stationary phase fungal cells that are
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inhaled from the environment or released from immune suppression, such an
environment is predicted to trigger the formation of Titan cells. Further studies should
establish common cellular features that promote Titan cell formation and will further
explain the basis for strain and species-based differences in this peculiar morphological
transition.
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IV. Elucidation of the Swe1 homologs in Cryptococcus neoformans

Rodney J. Colón-Reyes, Jin-Tae Choi, Seung-Heon Lee, Kathryn Counts, Megan
Prescott, Setareh Etesham, Yaliz Loperena-Alvarez, Yong-Sun Bahn, Lukasz
Kozubowski.

IV.1 INTRODUCTION

Human fungal pathogens have become more commonplace since the late 20th
century. With the advent of the AIDS pandemic, fungal infections came to the forefront
[1], and while that pandemic is far from its worst days, fungal infections are still very much
present in the lives of people with immunocompromised and immunocompetent systems
[2]. In looking to develop new antifungal therapies, the focus is to find an optimal drug
target on the pathogen, and to reduce the side effects on the host. That is why studying
the conserved eukaryotic cell cycle, and describing the connections between cell cycle
regulation, morphogenesis, and virulence could give us insights into how fungi proliferate,
and how these pathways link to virulence could give us insights into best possible drug
targets. [3] [4].
Cellular growth and division of the pathogen are central to virulence. Fungi, like
other eukaryotes, coordinate growth with nuclear and cellular division by a series of
ordered processes collectively known as the cell cycle. The eukaryotic cell cycle consists
of conserved process which are divided into four phases known as Gap1 (G1), Synthesis
(S), Gap2 (G2), and Mitosis (M) [4] [5]. The transitions between phases and the events
that happen in each stage must be executed in an orderly and timely manner [6]. This
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order is maintained by a combination of surveillance pathways known as checkpoints,
with the activity of cyclin-dependent kinases (CDKs) [7]. The checkpoints are a group of
pathways that are monitoring the key events and halt/delay the cell cycle progression
when the cell comes under undue stress causing physiological failure [8]. The most
studied checkpoints are surveilling DNA damage, DNA replication, and the proper
organization of the spindle pole bodies (SPBs) called the spindle assembly checkpoint
(SAC) [9]. The DNA damage checkpoint delays cell cycle progression in response to any
type of genotoxic insult [10]. This allows the cell to repair the damage and continue
through the cell cycle. The DNA replication or S-phase checkpoint works by slowing down
DNA replication by inhibiting origin firing and protects replication forks from becoming
double strand breaks (DSBs) when they are stalled [11]. The SAC is activated when the
two kinetochores on sister chromatids do not have bipolar orientation. This checkpoint
will stay activated until the correct kinetochores are attached to the spindle properly [12].
The CDKs are regulated by a multitude of proteins acting in different pathways.
They drive the cell cycle forward, functioning as a “highly conserved engine” [9]
maintaining control over the timely progression of the multiple transitions inherent in the
cell cycle. In the fission yeast, Schizosaccharomyces pombe, CDK is reversibly
phosphorylated at a THR167 residue and a highly conserved tyrosine residue (TYR15)
by a highly conserved tyrosine kinase known as Wee1; this phosphorylation inhibits CDK
activity [13] [14] [15]. The Saccharomyces cerevisiae CDK, Cdc28, is phosphorylated at
THR18 and a TYR19 residues, by the Wee1 homolog Swe1, also inhibiting activity [16]
[17]. This phosphorylation of CDK is an essential stop switch for the G2/M DNA Damage
Checkpoint [9] [15]. The phosphorylation needed for cell cycle control is undertaken by a
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group of serine-threonine kinases. Among these Chk1 is of relative importance since it
helps coordinate DNA damage response [18]. The activation of Chk1 is what starts the
cell cycle checkpoints, cell cycle arrests, and DNA repair among others. Chk1 is part of
the Atr1-Chk1-Wee1 pathway that controls G2/M and the S checkpoint [18]. It is Wee1
homologs that are responsible for the inhibitory phosphorylation of CDKs that results in
cell cycle arrest characteristic of cell cycle checkpoints.
The Wee1 protein family is a group of nuclear kinases that belong to the
serine/threonine kinases. Wee1 is a dosage-dependent inhibitor of mitosis [19]. This
inhibition of mitosis is mediated by the phosphorylation of CDKs by Wee1. This protein
family has been described in detail in at least four cell cycle checkpoints, with more recent
research reporting roles in additional checkpoints and other cellular processes. In
mammalian cells, Wee1 has been observed to have a regulatory role in DNA replication
the intra-S checkpoint [20] [21]. Wee1 maintains a dNTP pool, by controlling availability
of the pool through limiting CDK-driven origin firing. Wee1 also has a role in epigenetic
regulation as observed in human cells. Wee1 phosphorylates the histone H2B at the Y37 residue. This inhibits the binding of RNA polymerase II and the nuclear protein
coactivator of histone transcription [22] [20]. In S. pombe it has been described as part of
a cell size checkpoint. In both S. pombe and S. cerevisiae Wee1/Swe has been described
as the enforcer of the G2/M DNA damage checkpoint, preventing entry into mitosis in
response to DNA damage. Recent research has shed light on Wee1 role in S-phase
checkpoint. Wee1 suppresses CDK2, in human mammary gland cells, preventing origin
firing during replication fork stalling [21]. This prevents replication stress and mitotic
catastrophe from occurring.
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Swe1 has been described extensively in S. cerevisiae in what is called the
morphogenesis checkpoint. [23] This checkpoint is activated when budding is inhibited,
for instance because of actin depolymerization in response to some stressor. Swe1 levels
can be stabilized in response to multiple stressors such as: a damaged septin ring [24],
defects in cell wall synthesis, and DNA synthesis interruption by hydroxyurea or methyl
methanosulfonate [25] (MMS). In S. cerevisiae, Swe1 responds to the depolymerization
of actin [23] [16] [26]. Since budding is inhibited when actin depolymerizes and Swe1
needs to localize to the bud neck to be degraded, a pool of Swe1 is stabilized, maintaining
CDK inhibition through phosphorylation [27] [28]. This process prevents multiple nuclei
formation inside the mother cell. Once the insult to actin is resolved, the cell continues
transitioning to M phase. Wee1 was first described in the fission yeast,
Schizosaccharomyces pombe as a cell size regulator. Cells with Wee1 knocked out
divided faster [13] [29] [19] and resulted in smaller and smaller daughter cells. This was
named the “wee” phenotype.
The human pathogen Cryptococcus neoformans is a basidiomycetous yeast. With
over 180,000 reported deaths a year, cryptococcosis is one of the more deadly of the
systemic mycoses [30]. As a pathogen C. neoformans has characteristic virulence factors
that allow it to survive and proliferate in the mammalian host. Surprisingly for a deadly
pathogen, the cryptococcal cell cycle has been largely ignored as a potential explanation
for its capacity for virulence and survival. Studies have described how C. neoformans
contains only one CDK (Cdk1), which has a role in bud emergence and DNA synthesis
during G1 [31]. It also has only 1 G1 cyclin, a Cln1 homolog, that is not essential for
survival. While not essential, deletion of CLN1 causes a delay in budding, aberrant
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growth, and delayed DNA replication [31]. Recently, it has been reported that C.
neoformans can, through the activation of meiotic genes, mediate ploidy reduction [32].
The authors propose that polyploidization of C. neoformans is in response to genotoxic
stress that “causes DSB”, suggesting a role for the DNA damage checkpoint machinery
in this process. At the same time, it is proposed that the reduction on polyploidy by meiotic
genes ends in haploid progeny being able to proliferate through the immunocompromised
host.
Studies looking into a more direct connection between the cell cycle and virulence,
have looked into how virulence factors, such as the polysaccharide capsule, are
associated to cell cycle progression [33], while others have looked into the periodic
transcription of genes during cell cycle progression and how they relate to virulence [4]
[5], and some have looked into how septins contribute to virulence in C. neoformans [34].
Currently, morphogenetic changes [35] [6], such as titanization [36] [37], that the
yeast undergoes to survive in the mammalian host have been linked to the non-essential
(for non-stressed growth) CLN1 gene [3]. Since titanization is a morphogenetic change
and C. neoformans is a budding yeast-like fungus, there could be a role for Wee1
homologs in this process. Previous studies have reported Swe1 in C. neoformans as
essential for survival in mouse cerebral spinal fluid [38] (CSF). Another Wee1 homolog in
C. neoformans, Swe102, has been reported to be necessary for response to antifungal
drugs such as fluconazole and for high temperature stress response [39]. To our
knowledge, results presented here constitute the first study into the myriad roles of the
Wee1 homologs, including those that may influence the titanization morphogenesis.
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IV.2 Materials and Methods.

Strains and growth conditions.

Saccharomyces cerevisiae strains were routinely cultivated on Yeast extract
Peptone Dextrose supplemented with adenine hemisulfate (YPAD), followed by liquid
medium: 1% yeast extract, 2% bacto-peptone, 100 mg/mL adenine hemisulfate, and 2%
bacto-agar for semi-solid media. Glucose was filter sterilized and added to media to a
final concentration of 2%. For the DNA/PEG method, YPAD 2x was used and for semi
solid-media, 2% bacto-agar was added. In case of Titan induction experiment, cells were
grown overnight in 5 ml Yeast Nitrogen Base (YNB) liquid medium: 0.67% Yeast Nitrogen
Base with amino acids, pH 5.5 (Sigma cat. no. Y1250, St. Louis, MO, USA), 2% glucose
at 30°C with horizontal shaking at 220 rpm (Thermo Scientific, MAXQ4450).
Cryptococcus neoformans strains were routinely cultivated in (1% yeast extract, 2%
bacto-peptone, 2% glucose and 2% bacto-agar for semi-solid media (YPD).
For growth curves, cells were inoculated at 106 cells/mL in 100 mL of YPD or
YPAD, depending on the species. Samples were taken every 1.5 h for 8.5 h. These
samples were for OD600 measurements, protein analysis, microscopy, and flow cytometry
analysis. For growth assays, cells were grown overnight and refreshed in a 1:5 dilution of
overnight culture to fresh media and grown until cell density was 107 cells/mL. Serial
dilutions were then done and the resulting dilutions (104, 103, 102, 10) were spotted onto
YPD/YPAD, supplemented with various drugs and chemical reagents. For genotoxic
stress HU (100 and 110 mM for 48 h) or MMS (0.03 and 0.04% v/v for 72 hrs) was
added to YPD. For antifungal stress response, fluconazole (10 and 13 ug/mL for
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72 h), amphotericin b (1.6 and 1.8 ug/mL for 24 h), 5-FC (300 and 500 ug/mL for 72 h),
and fludioxonil (1 and 3 ug/mL for 48 h) were used. For osmotic stress two media were
used, YPD and YP (no dextrose). For YPD NaCl (1.5 mM), KCl (1.5 mM), and sorbitol (2
M) were used for 72 h incubation. For YP, NaCl (1 mM), KCl (1 mM), and sorbitol (2 M)
were used for 72 h incubation.
Strain Construction
The complemented Saccharomyces cerevisiae strains were generated using the
DNA/PEG method as previously described [40]. Transformants were generated using the
PDS-1000/HE Biolistic Particle Delivery System (BIO-RAD) to insert the plasmids
containing either the endogenous promoter to S. cerevisiae Swe1 or the Gal4 promoter
controlled Swe1/Swe102.
The C. neoformans strain with Swe1 under control of the CTR4 promoter was
generated as previously described [41]. Briefly, the left flanking region to Swe1 (ID:
CNAG_03171) or upstream of ATG and ORF were amplified and joined by overlap PCR.
The NAT-CTR4 promoter was amplified form plasmid pNAT-CTR4-2. The products were
joined by overlapped PCR and transformed into C. neoformans by biolistic transformation.
Transformants were confirmed by growth on YPD containing nourseothricin (100 mg/L).
Complementation of S. cerevisiae

The S. cerevisiae swe1Δ strain (a gift from the laboratory of Dr. Daniel Lew, Duke
University) was transformed with plasmids expressing Wee1 homologues from either the
endogenous ScSwe1 promoter or the Gal4-P promoter (induced by the presence of
galactose in the media). These plasmids were generated (Genscript) by using S.
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cerevisiae codon optimized ORFs of the CnSwe1 and CnSwe102 and sequences are
available upon request. The codon optimized ORFs were inserted into either the Gal4-P
background (pJM1101) or the ScSwe1 endogenous promoter background (pJM1115).
Plasmids were transformed into the swe1Δ strain using the DNA/PEG method with a
LiAc/SS carrier.
Galactose induction in Saccharomyces cerevisiae

Strains containing the Gal4-P plasmids (pJM1101 background) were grown
overnight in YPAD at 30˚C and 225 rpm. The plasmid maps can be seen in Fig. 4.2 Cells
were refreshed, 1:5 dilution, in the morning into yeast extract peptone adenine
supplemented with raffinose to 2% final concentration (YPAR). Growth in raffinose results
in non-induction and non-repression of the GAL promoter. This allows the regulatory
subunits for galactose induction to bind upstream of the genes that will be induced by the
presence of galactose. Cells were grown until late log phase and were then supplemented
with galactose to a final concentration of 2%. Cells were grown a minimum of 6 h before
harvesting and processing for immunofluorescence and protein extraction.

Latrunculin B treatment of S. cerevisiae strains expressing plasmids containing
the ScSwe1 endogenous promoter

Latrunculin B (Lat-B) is an actin depolymerizer that is used to inhibit budding in
yeast. Cells were grown until stationary phase in YPAD. Cells were then refreshed to 106
cells/mL and Lat-B (Cat. No. BML-T110-0001, Enzo Life Sciences, Inc.) stock solution
(20 mM DMSO) was added to the refreshed culture, to a final concentration of 100 uM
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Lat-B. Cells were grown for 6 h before harvesting for protein extraction and
immunofluorescence (IF).
Western Blot Analysis

Protein extraction was performed using the following TCA protocol. Briefly, cells
were grown to log phase before harvesting. 1-1.5 mL of cell culture was spun down in a
microcentrifuge for 3 minutes at ~10,000xg. Supernatant was discarded and pellet
resuspended in 225 µL of Pronase Buffer (1.4 M Sorbitol, 25 mM Tris-HCL pH 7.5, 20
mM NaN3, 2 mM MgCl2, ddH2O to 10 mL). Once resuspended, 56 uL of 85%
Trichloroacetic acid, 6.1 N solution, MP Biomedicals (TCA) were added. This solution was
transferred to sterile cryotubes containing 280 uL of acid-washed 425–600-micron glass
beads. Tubes were then vortexed in a bead beater in eight, twenty second cycles with a
two-minute rest between cycles at 4˚C. After lysis of the cells, tubes were incubated on
ice for 10 minutes. The samples were transferred to fresh, sterile microcentrifuge tubes.
The glass beads were washed twice with 280 uL of 5% TCA and the wash was added to
the samples in the microcentrifuge tubes. The cell lysates were incubated for 5 minutes
on ice, then centrifuged at 11,000 rpm for 10 minutes at 4˚C. Supernatant was discarded
and the pellet was solubilized in 30 uL of Thorner Buffer (8M Urea, 5% SDS, 40 mM TrisHCl pH 6.8, 0.1 mM EDTA, 0.4 mg/mL bromophenol blue). If samples turned yellow or
green, up to 10 uL of unbuffered 2 M TRIS Base was added until samples turned blue.
To denature the proteins, BME to a final concentration of 1% was added to each sample.
Protein samples were loaded unto NuPAGE 4-12% Bis-Tris Gel (Cat. No.
NP0335BOX, Invitrogen, Thermo Fisher Scientific) and run at 150V for 55 minutes in the
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Invitrogen Mini Gel Tank (Cat. No. A25977, Thermo Fisher Scientific) using a MOPS
running buffer (MOPS 0.1 M, Tris Base 0.1 M, SDS 6.93 mM, EDTA free acid 2.05 mM,
complete to 1 L with ddH2O). Protein was immobilized to a PVDF membrane (Immobilon
Transfer Membranes, Ref. IPFL07810, Merck Millipore Ltd.). The Invitrogen Mini Gel
Tank was used with the Mini Blot Module (Cat. No. B1000, Thermo Fisher Scientific) to
transfer unto the PVDF membrane using the 1x NuPAGE Transfer Buffer (Cat. No.
NP0006, Thermo Fisher Scientific). The resulting PVDF membrane was stained with
Ponceau S to confirm transfer of protein samples. Briefly, 10 mL of Ponceau S was added
to the PVDF membrane and incubated for overnight, at RT, with constant shaking. After
confirming the protein transfer, Ponceau S was washed out with TBST1x (Tris-Buffered
Saline plus Tween20) for 30 minutes, twice, with constant shaking. Membrane was
blocked with 5% BSA in 1x TBST, for 1 h at room temperature. Primary antibody was
added overnight in constant shaking at 4ºC. The primary antibodies used in this study
include anti-phospho-Cdc2 (Tyr15) (Cat. No. 9111, Cell Signaling) to detect
phosphorylation of Cdk1 by Wee1 homologs, and anti-PSTAIR (Cat. No. P7962, Sigma)
to detect total Cdk1 protein. Blots were developed with HRP-labeled secondary
antibodies using the SuperSignal West Pico Chemiluminescent Substrate (Cat. No.
34580, Thermo Fisher Scientific).
Immunofluorescence and Flow Cytometry

For DNA content analysis using fluorescence flow cytometry, approximately 107
cells were harvested, spun down in a microcentrifuge at 13,000 x g, supernatant
discarded and fixed with 70% ethanol overnight at 4˚C. The next day cells were spun
down and washed with a 1x Citrate solution (0.890 μM Citric Acid, 0.491 M Sodium
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Citrate) and spun down again. Pellet was resuspended in 1mL 1x Citrate supplemented
with RNAse A (0.25 mg/mL) and SYTOX Green (500 nM). Tubes were covered with foil
and incubated at 4˚C overnight. Solution was sonicated before proceeding to flow
cytometry analysis using a Cytoflex Flow Cytometer (Beckman Coulter Life Sciences).
For immunofluorescence 5mL of YPAD were inoculated with S. cerevisiae, grown
overnight at 30˚C and 220 rpm. The overnight culture was diluted 1:20 in fresh YPAD and
grown at 30˚C to a density ~1-2x107 cells/mL. When this density was reached, 0.5mL
37% formaldehyde was added and incubated at 30˚C, 200 rpm for 2 hours. Culture was
centrifuged for 2 minutes at 1500xg and washed with 1X PBS and centrifuged. Pellet was
washed with Solution A (100 mM KPO4 (pH=6.5), 0.5 mM MgCl2, 1.2 M sorbitol),
centrifuged, and resuspended in 1 mL of Solution A. Cell wall was digested by adding
10 uL of BME and 50 uL of lyticase 10 mg/mL (Zymolyase 100T Concentrate 10 mg/mL,
0.1 M Sorbitol, Lyticase, Yeast Lytic Enzyme, US Biological Cat #: Z100) and incubating
at 37˚C for 20 minutes. Cells were then centrifuged at ~1500xg for 5 minutes at room
temperature. They were then washed twice with Solution A and once with 1X PBS and
centrifuged for 5 minutes at ~1500xg. The pellet was then resuspended in 600uL of 1X
PBS/1% BSA. To immunofluorescence microscopy slides (Polysciences, Inc.,
Microscope slides, immunofluorescence, Cat. #183571), 5 ul 0.1% polylysine (Sigma, P1524) were added to each well. After 30 seconds polylysine was aspirated and washed
three times with ddH2O. To each well, 5 uL of the lyticase treated cell were added and
let stand for 30-60 seconds. Cells were aspirated and slide let to dry until well turned
opaque (~5 minutes). To each well 2 uL of 0.1% SDS was added and let stand for 5
minutes at room temperature. Wells were washed 8 times with 1X PBS/1% BSA and
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5 uL of primary antibody was added to each well and incubated in a moist chamber
overnight at 4˚C. Slides were taken from the moist chamber and antibody was
aspirated. Wells were washed 8 times with 1X PBS/1% BSA and 5 uL of secondary
antibody were added to each well and incubated at room temperature for 1 hour in the
moist chamber and in the dark. Antibody was then aspirated and well washed 8 times
with 1X PBS/1%BSA. Without letting the wells dry, 5 uL of ProLong Glass Antifade
Mount with NucBlue stain (Thermo Fisher Scientifc Cat. # P36981) were added to each
well and a coverslip put on the slide. Coverslip and slide were pressed with a weight for
5 minutes, and then allowed to incubate in the dark at room temperature for 14-16
hours. The slides were then imaged.
Microscopy and Image Acquisition

All microscopic images were taken on a LEICA DMi8 (LEICA Microsystems GmbH)
inverted microscope using the Leica Application Suite (LAS) X software to analyze them.
Cell count was performed using Fiji Madison version.

IV.3 Results

C. neoformans Swe1 and Swe102 have a characteristic conserved domain.

Ascomycetous budding yeasts depend on having an intact septin collar to degrade
Swe1 and allow the cell cycle to continue through cytokinesis [27] [34]. In the fission yeast,
Wee1 is an essential part of the cell size checkpoint [14]. In both cases, the Wee1/Swe1
homologs function by enforcing a reversible inhibition of CDKs by phosphorylation of a
conserved TYR15 residue [23] [16] [19] [17]. The Wee1 family of protein kinases contain
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a PTKc_Wee1_fungi domain toward the C-terminus, which the C. neoformans Wee1
homologs contain (Fig. 4.1). When compared to the S. pombe and S. cerevisiae protein
structure, the PTKc_Wee1_fungi domain is present, yet the rest of the C. neoformans
homologues have distinct domains. CnSwe1 has a Herpes_ICP4_C superfamily domain,
with the ICP4 (infected cell protein 4) being a transcriptional regulator which has a “central
role” [42] in herpes viral infection. The Atrophin A superfamily domain is found in Atrophin1, which has not been characterized yet. The Atrophin protein domain seems to be a
transcriptional co-repressor, meaning it possibly interacts with DNA binding proteins to
inhibit transcription indirectly [43].

Figure 4. 1 Cryptococcus neoformans Swe1 homologs have conserved active site
and domain.
While the Swe1 homologs are of different size, the PTKc_Wee1_fungi domain is always
found toward the C-terminus and is conserved in C. neoformans Wee1 homologues.
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The Cnswe1Δ strain is hypersensitive to multiple stressors

To determine the role of CnSwe1, a deletion of the gene encoding this protein was
performed in C. neo. The systemic pathogenic fungi need to react to multiple stressors to
guarantee survival and proliferation in the human host. The nature of these stressors will
vary in mode of action and cell response to them. As Figure 4.2 illustrates, the Cnswe1∆
strain is hypersensitive to heat shock (4.2a) and to four antifungals: amphotericin b,
fludioxonil, 5-FC, and fluconazole (4.2b). The four antifungals function in different
pathways.
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Figure 4. 2 The Cnswe1∆ strain is hypersensitive to high temperatures and various
antifungals.
The single deletion was compared to both wild-type and a hog1Δ strain. Hog1 is
necessary for response to multiple stressors, which makes strains missing this protein a
good candidate for a positive control.
CnSwe1 is involved in response to osmotic (Fig. 4.3a), oxidative (Fig. 4.3b), and
genotoxic stress (Fig. 4.3c). Figure 4.3 shows the hypersensitivity of the Cnswe1∆ strain
to these stressors. For osmotic stress NaCl, KCl, and Sorbitol 2 M were used to stress
the cryptococcal cells. Oxidative stress was tested for by using t-BOOH and menadione,
with the former behaving similarly to H2O2 and the latter is a vitamin K precursor.
Genotoxic stress response was tested by incubating the cells either with hydroxyurea
(HU) or methyl methanosulfonate (MMS).
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Figure 4. 3 The Cnswe1∆ strain shows increased sensitivity to osmotic, oxidative,
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and genotoxic stress.
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CnSwe1 and CnSwe102 have redundant roles and demonstrate synthetic lethality.

The two Wee1 homologs seem to have important roles in fludioxonil resistance
(FDX), cell wall stress response and a diminished thermal tolerance when compared to
the wild type (Fig. 4.4A). Strikingly, both homologs seem to be interacting with each other
in a synthetic lethal matter. The Cnswe1Δ and Cnswe102Δ strains are incapable of
mating with each other. After 2 weeks of incubation on MS Media, no basidia, hyphae or
basidiospores were present. After 3 weeks some hyphae were present, but no
basidiospores were ever observed (Fig. 4.4B). We were not able to generate the double
deletion mutant through biolistics or split-marker technique; this points to the possibility
that eliminating these two genes is synthetic lethal.
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a

b

Figure 4. 4 CnSwe1 and CnSwe102 have redundant roles and demonstrate
synthetic lethality.

a) CnSwe1 and CnSwe102 have redundant roles in fludioxonil, cell membrane, and high
temperature stress response. b) CnSwe1 and CnSwe102 appear to be synthetic lethal
Titanization and the Swe1 homologs

To ask whether the Swe1 homologs played a role in titanization, we used a
Cnswe1∆ strain (YSB 8309) and a Cnswe102∆ strain (YSB 1564). We subjected these
strains to the in vitro titanization protocol as established by Dambuza et al [44]. After 5
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days of incubation under the titanization conditions, the cells were harvested and
prepared for India Ink staining and light microscopy. The cells were immobilized by
dropping 5 μl of the stained culture on a microscope glass slide that had a 1% agarose
patch on the slide.
The Cnswe1∆ strain had Titan cells with healthy looking cell bodies, while the
enlarged polysaccharide capsule showed an irregular capsule shape (Figure 4.5b). It
appears that CnSwe1 has a role in the formation of the capsule. Previous research has
shown that capsule growth in C. neoformans is coordinated with the cell cycle. A mutation
in the CDK associated cyclin proteins resulted in a capsule bigger than the one produced
by the wild-type strain. Even with a bigger capsule, the strain was avirulent at 37˚C [33].
This seems to be caused by an increase of extracellular vesicle (EVC) production. These
ECV take the capsule components (GXM) to the cell wall to be added into the currently
growing capsule. Unfortunately, the capsule does not inhibit phagocytosis in this strain,
even when grown in rich media. Titanization is characterized by an increase in cell body
and capsule size. Swe1 is an important component of Cdk1 regulation and thus helps
control cell cycle progression. It seems that an intact Swe1 is needed for the titanization
capsule formation to happen correctly.
The Cnswe102∆ strain subjected to titanization conditions showed an elongated
phenotype, similar to those called pseudohyphae (data not shown). This elongation has
a resemblance with the characteristic phenotype of the Morphogenesis Checkpoint in S.
cerevisiae. When ScSwe1 is over-expressed, elongated phenotypes result since the
yeast cannot continue the cell cycle towards mitosis. After analyzing the resulting
phenotypes from the single deletion mutants, we proceeded to use a strain with Swe1
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under the control of an inducible/repressible copper uptake promoter and the Cnswe102∆
to see if inhibiting CnSWE1 transcription in the absence of CnSwe102 affected
titanization. After repressing the CnSwe1 promoter with the addition of copper, the
resulting cells appeared with a healthy cell body, but with a capsule that seemed smaller
than the one found in the single deletion mutants. This gives a support to our hypothesis
that CnSwe1 is more involved in the coupling of capsule growth and the cell cycle, while
CnSwe102 is involved in coordinating cell division with the titanization induced growth.
Regarding their sizes, Cnswe102∆ strain showed an average area of 29.58 µm, while
Cnswe1∆ and the Cnswe102Δ PCTR4:SWE1 strain had average areas of 36.57 µm and
51.85 µm, respectively.

a

b
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Figure 4. 5 Role of Wee1 homologs in titanization.
a) Cnswe102Δ PCTR4:SWE1 b)Cnswe1Δ strain c) distribution of cell area of titanized mutants

CnSwe1 and CnSwe102 do not localize at the C. neoformans bud neck
Previous research has shown that in S. cerevisiae Swe1 is exported from the
nucleus once a bud neck forms and is localized to the bud neck for its timely degradation
to allow cell cycle progression. We had observed that when the septin scaffolding at the
bud neck is disturbed in C. neoformans, cellular division continued as normal under nonstress conditions. In S. cerevisiae any disturbance to the septin scaffolding results in
stabilization of Swe1, preventing the budding yeast from dividing and leading to a
characteristic elongated bud phenotype. This observation suggests that disturbing the
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cryptococcal bud neck does not result in a typical Morphogenesis Checkpoint.
Consequently, we would not expect the C. neoformans Wee1 homologues to localize to
the mother-bud neck. To test this possibility, we complemented the Cnswe1∆ and the
Cnswe102∆ strains with the mCherry-tagged chimeras of CnSwe1 and CnSwe102,
respectively, to analyze the localization of the Wee1 homologues with fluorescence
microscopy.
When cells were analyzed, it was observed that complementation of the Cnswe1∆
and the Cnswe102∆ with the Cnswe1-mCh and CnSwe102-mCh, respectively, results in
the recovery of the wild-type phenotype as seen in Figure 4.6 for CnSwe102, CnSwe1
(data not shown) Once we imaged the complemented strains, we were able to detect a
small signal that localizes near the nucleus (Fig. 4.7A for Swe1 and 4.7B for Swe102).
Our data seem to indicate that Swe1 is localized inside the cell nucleus, where it may
inhibit Cdc28 directly. We propose that not only does Swe1 and Swe102 localize to the
nucleus, but that they also localize to the spindle pole body (SPB). The reasoning
supporting this statement stands by the fact of the localization and accumulation of Wee1
to the SPB during the G2/M transition that has being reported in S. pombe. Here, Wee1
accumulates on the nuclear face of the SPB and regulates the spindle assembly [45].
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Figure 4. 6 Swe1 and Swe102 are complemented by their wild type
gene tagged with mCherry.
Complementing the swe1∆ strain confirms its roles in SDS and fluconazole
resistance, while complementing the swe102∆ confirms its role in anti-fungal
resistance.

121

Figure 4. 7 Swe1-mCh and Swe102-mCH localize to the nucleus during
stationary phase.
CnSwe1 and CnSwe102 may phosphorylate CnCdk1, can phosphorylate the S.
cerevisiae Cdc28 and complement phenotype of the Scswe1∆ strain.
While it appears that there is no Morphogenesis Checkpoint in C. neoformans,
CnSwe1 and CnSwe102 could nonetheless participate in other cell cycle checkpoints by
phosphorylating C. neoformans CnCdk1. To test this possibility, we first analyzed if the
phosphorylation of C. neoformans CnCdk1 on a conserved phosphorylated residue is
affected by the absence of either of the Wee1 homologues. Strikingly the phosphorylation
seemed not affected by eliminating either of the genes (Figure 4.8 A). These results seem
to confirm the redundancy of the Wee1 homologs in C. neoformans.
To circumvent a possible issue with the putative redundant roles of the Wee1
homologues in C. neoformans, we complemented the S. cerevisiae Scswe1∆ strain
(lacking the only Wee1 homologue in this species) with plasmids containing either the
CnSwe1 or CnSwe102 homologs tagged at the C-terminus with 12x-myc epitope and
expressed from either the Gal4 promoter or an endogenous promoter (Fig. 4.9). The goal
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of this approach was twofold: to test if the C. neoformans Wee1 homologues are capable
of phosphorylating the S. cerevisiae CDK, Cdc28, and 2. to test if these cryptococcal
proteins can trigger the Morphogenesis Checkpoint when expressed at endogenous
levels or overexpressed in baker's yeast. As the endogenous Swe1 is not highly
expressed in S. cerevisiae, tagging the Wee1 homologues with several copies of myc
[27. At the same time a 12x -myc tag allowed for immunofluorescence to be performed
and allowed for visualization of the localization of the Wee1 homologues. Overexpressing
CnSwe1 or CnSwe102 resulted in an elongated phenotype in the S. cerevisiae cells (Fig
4.9C), which is characteristic for the block in the transition from the apical to isotropic
growth. When expressed under the control of the GAL4 promoter, CnSwe102 resulted in
47.7% elongated cells (n=131) and CnSwe1 resulted in 64.41% elongated cells (Fig.
4.7A) (n=118). When ScSwe1 was expressed under control of the galactose promoter,
elongated cells were 63.6% of all cells (n=152), while the Scswe1Δ strain produced
97.33% non-elongated cells, with only 2.67% of cells elongated (Fig.4.9A). Strikingly the
immunofluorescence results indicated that the elongated cells are the ones with the
highest levels of the Wee1 homologues. The results of the immunofluorescence with the
endogenous promoter strain were not as the one expected, as we could not detect the
Wee1 at the mother-bud neck, but we were able to observe phosphorylation states of the
S. cerevisiae Cdc28 (4.8C). in all strains, tested in these experiments. These results
seem to confirm the redundancy of the Swe1 homologs in C. neoformans, as we can
observe with the western blots that each homolog can phosphorylate CDK1 in the
absence of the other, in Figure 4.8A.
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Figure 4. 8 Cryptococcus neoformans Swe1 and Swe102 may phosphorylate
CnCdk1.
a) Swe1 and Swe102 may phosphorylate Cdk1 at the TYR15 residue independently of
one another. B) Cryptococcus neoformans CnSwe1 and CnSwe102 can phosphorylate
CDC28 in S. cerevisiae.
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Cryptococcus neoformans Swe1 and Swe102 can complement the S. cerevisiae
wild-type phenotype.
Yeast cells expressing the C. neoformans Wee1 homologues from the S.
cerevisiae endogenous promoter partially recovered their phenotype of single nucleus
when actin was depolymerized by latrunculin B (LatB). Expression of CnSwe1 resulted in
a 60.07% single nucleus cells (n=142) while expression of CnSwe102 resulted in 60.9%
single nucleus cells (n=82). When the ScSwe1 was expressed under the endogenous
Swe1 promoter, 65.84% of cells had single nucleus (n=122). The wild type strain, S288c,
had 90.4% single nucleus cells (n=125). We could observe that when ScSwe1, CnSwe1
or CnSwe102 are in an ectopically (not integrated) expressed plasmid, the percent of
single nucleus cells is lower than those of the wild type (Fig. 4.9 B). When we compare
these complemented strains to the Scswe1Δ, we have 57.06% (n=163) of cells are
multinucleated when treated with LatB, with only 42.94% having a single nucleus. As we
can see, the wild type phenotype is complemented albeit not completely most likely due
to the nature of the expression of the plasmids.
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Figure 4. 9 C. neoformans CnSwe1 and CnSwe102 partially recover wild type
phenotype in S. cerevisiae lacking the endogenous ScSwe1
A. Overexpression of Swe1 homologs results in elongated phenotype in S. cerevisiae.
B. The C. neoformans Swe1 homologs recover the single nucleus phenotype in S.
cerevisiae. C. Immunofluorescence shows localization of Swe1 and Swe102 when
overexpressed in S. cerevisiae
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Treatments of C. neoformans mutants lacking the Wee1 homologues with the
agents disrupting replication result in aneuploidy and point to an S-phase
checkpoint role for CnSwe1 and CnSwe102
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Figure 4. 10 Treatment of WEE1 mutants with DNA damaging agents seems to
cause aneuploidy.
Red line indicates cells with 2n DNA content; wild type (WT) strain contain an overall
least amount of polyploidy while the mutant strains treated with DNA damaging agents
indicate an increase in DNA content compared with the WT strains similarly treated.
Cells with no exposure to DNA damaging agents showed lower prevalence of polyploidy
as compared to strains subjected to treatment with DNA damaging agents.

The Cnswe1∆ and the Cnswe102∆ deletion strains, when treated with DNA
damaging agents, suggest an increase in the S-phase population as observed by flow
cytometry. Further study should be dedicated to the role of Swe1 and Swe102 in S-phase
regulation and checkpoints in C. neoformans.

IV.4 Discussion
Our study provides evidence of the conserved functions of the C. neoformans
Wee1 homologs as a tyrosine kinase and as a key regulator in the G2/M Checkpoint and
a surprising role in the S-phase checkpoint. Studies in non-S. cerevisiae organisms have
concentrated on describing the relationship between the Swe1/Wee1 kinases and DNA
damage repair [46] [10] [47]. The Cnswe1∆ strain demonstrated a higher sensitivity to
both HU and MMS, pointing at the SWE1 homolog having the conserved function in the
G2/M DNA damage checkpoint in C. neoformans. At the same time, when cells lacking
CnSwe1 are treated with the same genotoxic agents, there is a change in ploidy of the
cell population. The population divides into a smaller haploid population and an increase
in both diploid and aneuploid. This aneuploidy could help explain why the pretreated C.
neoformans strains show a relative increase in the fluconazole stress response. Previous
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research from our group has shown that aneuploidy results from the uncoupling of cell
division from nuclear division, as a direct result of fluconazole treatment [48].
The evidence for the phosphorylation of the Cdk1 in C. neoformans by the CnSwe1
and CnSwe102 could not be clearly established but this could result from a redundancy
between these two Wee1 homologues. In support of this possibility, both homologues
were capable of phosphorylating Cdc28 in S. cerevisiae. Furthermore, their ectopic
heterologous overexpression in this species led to a characteristic elongated phenotype
in a large proportion of cells that showed overexpression of these proteins, which
reinforces the idea that both, CnSwe1 and CnSwe102 operate as bona fide Wee1
homologues in C. neoformans. The single deletions show slight aneuploidy increase
when grown under LatB treatment (data not shown), which points to a possible dosedependent manner in how CnSwe1 and CnSwe102 regulate mitosis. This has been
reported in S. pombe [19] previously and is a mechanism that should be studied in more
detail.
Previous work has established the need for CnSwe1 and CnSwe102 to be present
for infection in a mice model [38] [49]. Our study reports the importance of CnSwe1 for
genotoxic and osmotic stress response as well as thermal tolerance. All three stressors
are affecting C. neoformans once it enters the host.

IV.5 Conclusion
Taken together our findings suggest that the roles of CnSwe1 and CnSwe102 have
evolved to make C. neoformans adaptive enough to survive the environmental niche it
occupies in the mammalian hosts where it causes disease. They also suggest C.
neoformans has no canonical Morphogenesis Checkpoint as described by McMillan et al
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[16]. We propose that C. neoformans budding reproduction notwithstanding, should be
studied as one of the systematic dimorphic fungi. We propose that the two Wee1
homologues have redundant roles in DNA damage repair pathways, for which CnSwe1
and CnSwe102 can take over the functions of the other homolog when they are missing
in the cell. At the same time, these two homologs are not out sensing for a bud to form,
but are involved in size regulation, capsule formation, and overall growth of the yeast cell.

129

IV.6 References

[1] A. Casadevall, «Fungal Diseases in the 21st Ccentury: The Near and Far Horizons, »
Pathogens and
Immunity, vol. 3, nº 2, pp. 183-196, 2018.
[2] G. Brown, D. Denning, N. Gow, S. Levitz, M. Netea and T. White, «Hidden killers: human
fungal infections,» Sci Transl Med, vol. 4, nº 165, 2012.
[3] S. Altamirano, K. Jackson and K. Nielsen, «The interplay of phenotype and genotype in
Cryptococcus neoformans disease, » Bioscience Reports, vol. 40, 2020.
[4] C. M. Kelliher, A. R. Leman, C. S. Sierra and S. B. Haase, «Investigating Conservation of
the Cell-Cycle- Regulated Transcriptional Program in the Fungal Pathogen, Cryptococcus
neoformans, » PLoS Genetics, vol. 12, nº 12, p. e1006453, 2016.
[5] C. Kelliher and S. Haase, «Connecting virulence pathways to cell-cycle progression in the
fungal pathogen Cryptococcus neoformans, » Curr Genet, vol. 63, pp. 803-811, 2017.
[6] J. Lin, A. Idnurm and X. Lin, «Morphology and its underlying genetic regulation impact the
interaction between Cryptococcus neoformans and its hosts., » Medical Mycology, vol. 53,
pp. 493-504, 2015.
[7] N. Brown, S. Korolchuk, M. Martin, W. Stanley, R. Moukhametzianov, M. Noble and J.
Endicott,
«CDK1 structures reveal conserved and unique features of the essential cell cycle CDK, »
Nature Communications, vol. 6, nº 6769, 2014.
[8] K. Barnum and M. O'Connel, «Cell Cycle Regulation by Checkpoints, » Methods Mol Biol,
vol. 1170, pp. 29-40, 2014.
[9] R. Poon, «Cell Cycle Control: A System of Interlinking Oscillators, » de Cell Cycle
Oscillators: Methods and Protocols, vol. 1342, A. Coutts y L. Weston, Edits., New York,
Springer Science + Business Media New York 2016, 2016.
[10] O. Ballew and S. Lacefield, «The DNA damage checkpoint and the spindle position
checkpoint: guardians of meiotic commitment, » Curr Genet, vol. 65, nº 5, pp. 1135-1140,
2019.
[11] O. Ballew and S. Lacefield, «The DNA Damage Checkpoint and the Spindle Position
Checkpoint Maintain Meiotic Commitment in Saccharomyces cerevisiae, » Current
biology, vol. 29, nº 3, pp. 449-460.e2, 2019.
[12] M. Segurado and J. Tercero, «The S-phase checkpoint: targeting the replication fork, » Biol
Cell, vol. 101, nº 11, pp. 617-627, 2009.

130

[13] P. Nurse, P. Thuriax and K. Nasmyth, «Genetic control of the cell division cycle in the
fission yeast
Schizosaccharomyces pombe, » Mo. Gen. Genet., vol. 146, pp. 167-178, 1976.
[14] D. Kellog, «Wee1-dependent mechanisms required for coordination of cell growth and cell
division, » J Cell Science, vol. 116, pp. 4883-4890, 2003.
[15] J. Raleigh and M. O'Connell, «The G2 DNA damage checkpoint targets both Wee1 and
Cdc25, »
Journal of Cell Science, vol. 113, pp. 1727-1736, 2000.
[16] J. N. McMillan, R. A. Sia and D. J. Lew, «A Morphogenesis Checkpoint Monitors the Actin
Cytoskeleton in Yeast, » Journal of Cell Biology, vol. 142, nº 6, pp. 1487-1499, 1998.
[17] R. A. Sia, H. A. Herlad and D. J. Lew, «Cdc28 Tyrosine Phosphorylation and the
Morphogenesis Checkpoint in Budding Yeast, » Molecular Biology of the Cell, vol. 7, pp.
1657-1666, 1996.
[18] H. Smith, H. Southgate, D. Tweddle and N. Curtin, «DNA damage checkpoint kinases in
cancer, »
Expert Rev Mol Med, vol. 22, p. e2, 2020.
[19] P. Russell and P. Nurse, «Negative regulation of mitosis by wee1+, a gene encoding a
protein kinase homolog, » Cell, vol. 49, nº 4, pp. 559-67, 1987.
[20] S. Koh, «The expanding role of Wee1, » Cellular Signaling, vol. 94, 2022.
[21] A. Woodward, T. Gohler, M. Luciani, M. Oehlmann, X. Ge, A. Gartner, D. Jackson and J.
Blow, «Excess Mcm2–7 license dormant origins of replication that can be used under
conditions of replicative stress, » J Cell Bio, vol. 173, nº 5, pp. 673-683, 2006.
[22] K. Mahajan and N. Mahajan, «WEE1 Tyrosine Kinase, A Novel Epigenetic Modifier, »
Trends Genet.,
vol. 29, nº 7, pp. 394-402, 2013.
[23] D. J. Lew and S. I. Reed, «A Cell Cycle Checkpoint Monitors Cell Morphogenesis in
Budding Yeast, »
The Journal of Cell Biology, vol. 129, nº 3, pp. 739-749, 1995.
[24] V. Cid, M. Shulewitz, K. McDonald and J. Thorner, «Dynamic localization of the Swe1
regulator Hsl7 during the Saccharomyces cerevisiae cell cycle, » Mol Biol Cell, vol. 12, nº
6, pp. 1645-69, 2001.
[25] L. Matellán and F. Monje-Casas, «Regulation of Mitotic Exit by Cell Cycle Checkpoints:
Lessons from Saccharomyces cerevisiae, » Genes, vol. 195, 2020.
[26] R. Sia, H. Herald and D. Lew, «Cdc28 tyrosine phosphorylation and the morphogenesis
checkpoint in budding yeast, » Mol Biol Cell, vol. 7, pp. 1657-1666, 1996.

131

[27] J. N. McMillan, C. L. Theesfeld, J. C. Harrison, E. S. Bardes and D. J. Lew, «Determinants
of Swe1p Degradation in Saccharomyces cerevisiae, » Molecular Biology of the cell, vol.
13, pp. 3560-3575, 2002.
[28] R. A. Sia, E. S. Bardes and D. J. Lew, «Control of Swe1p degradation by the
morphogenesis
checkpoint, » The EMBO Journal, vol. 17, nº 22, pp. 6678-6688, 1998.
[29] P. Nurse, «Genetic control of cell size at cell division at yeast, » Nature, vol. 256, pp. 547551, 1975.
[30] C. f. D. Control, «C. neoformans Infection,» [En línea]. Available:
https://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/index.html. [Último
acceso: 30 05 2022].
[31] E. Virtudazo, S. Kawamoto, M. Ohkusu, S. Aoki, M. Sipiczki and K. Takeo, «The single
Cdk1-G1 cyclin of Cryptococcus neoformans is not essential for cell cycle progression but
plays important roles in the proper commitment to DNA synthesis and bud emergence in
this yeast, » FEMS Yeast Research, vol. 10, nº 5, pp. 605-618, 2010.
[32] Y. Zhao, Y. Wang, S. Upadhyay, C. Xue and X. Lin, «Activation of Meiotic Genes Mediates
Ploidy Reduction during Cryptococcal Infection, » Curr Biol, vol. 30, pp. 1387-1396, 2020.
[33] R. Garcia-Rodas, R. Cordero, N. Trevijano-Contador, G. Janbon, F. Moyrand, A.
Casadevall and O. Zaragoza, «Capsule growth in Cryptococcus neoformans is
coordinated with cell cycle progression, » mBio, vol. 5, nº 3, 2014.
[34] L. Kozubowski and J. Heitman, «Septins Enforce Morphogenetic Events during Sexual
Reproduction and Contribute to Virulence of Cryptococcus neoformans, » Molecular
Microbiology, vol. 75, nº 3,
pp. 658-675, 2010.
[35] Z. Li and K. Nielsen, «Morphology changes in human fungal pathogens upon interaction
with the host, » J Fungi (Basel), vol. 3, nº 4, p. 66, 2017.
[36] O. Zaragoza and K. Nielsen, «Titan cells in Cryptococcus neoformans: cells with a giant
impact,»
Current Opinion in Microbiology, vol. 16, pp. 409-413, 2013.
[37] L. Okagaki and K. Nielsen, «Titan cells confer protection from phagocytosis in
Cryptococcus neofomans infections, » Eukaryot Cell., vol. 11, nº 6, pp. 820-826, 2012.
[38] A. Lee, D. Toffaletti, J. Tenor, E. Soderblom, J. Thompson, M. Moseley, M. Price and J.
Perfect,
«Survival Defects of Cryptococcus neoformans Mutants Exposed to Human Cerebrospinal
Fluid Result in Attenuated Virulence in an Experimental Model of Meningitis, » Infect
Immun, vol. 78, nº 10, pp. 4213-4225, 2010.

132

[39] K.-T. Lee, Y.-S. So, D.-H. Yang, K.-W. Jung, J. Choi, D.-L. Lee, H. Kwon, J. Jang, L. L.
Wang, S. Cha, G. L.
Meyers, E. Jeong, J.-H. Jin, Y. Lee, J. Hong, S. Bang, J.-H. Ji, G. Park, H.-J. Byun, S. W.
Park, Y.-M. Park, G. Adedoyin, T. Kim, A. F. Averette, J.-S. Choi, J. Heitman, E. Cheong,
Y.-H. Lee and Y.-S. Bahn,
«Systematic functional analysis of kinases in the fungal pathogen Cryptococcus
neoformans, » 28
Sep 2016. [En línea]. Available: https://www.nature.com/articles/ncomms12766.pdf.
[40] R. Gietz and R. Schiestl, «High-efficiency yeast transformation using the LiAc/SS carrier
DNA/PEG
method».
[41] M. Kim, Y. Ko, S. Maeng, A. Floyd, J. Heitman and Y. Bahn, «Comparative Transcriptome
Analysis of the CO2 Sensing Pathway Via Differential Expression of Carbonic Anhydrase
in Cryptococcus neoformans,» Genetics, vol. 185, nº 4, pp. 1207-129, 2010.
[42] R. Tunnicliffe, M. Lockhart-Cairns, C. Levy, A. Mould, T. Jowitt, H. Sito, C. Baldock, R.
Sandri-Goldin and A. Golovanon, «The herpes viral transcription factor ICP4 forms a
novel DNA recognition complex, » Nucleic Acid Res, vol. 45, nº 13, pp. 8064-8078, 2017.
[43] L. Wang and C. Tsai, «Atrophin proteins: an overview of a new class of nuclear receptor
corepressors, » Nucl Recept Signal, 2008.
[44] I. Dambuza, T. Drake, A. Chapuis and et al, «The Cryptococcus neofomans Titan cell is
an inducible and regulated morphotype underlying pathogenesis, » PLoS Pathog, vol. 14,
nº 5, p. e1006978, 2018.
[45] J. Lengefeld, M. Hotz, M. Rollins, K. Baetz and Y. Barral, «Budding yeast Wee1
distinguishes spindle pole bodies to guide their pattern of age-dependent segregation, »
Nature Cell Biology, vol. 19, pp. 941-951, 2017.
[46] M. Chang, M. Bellaoui, C. Boone and G. Brown, «A genome-wide screen for
methyl methanesulfonate-sensitive mutants reveals genes required for S phase
progression in the presence of DNA damage, » PNAS, vol. 99, nº 26, pp. 1693416939, 2002.
[47] R. Palou, G. Palou and D. Quintana, «A role for the spindle assembly checkpoint in the
DNA damage response, » Curr Genet, vol. 63, pp. 275-280, 2017.
[48] S. Altamirano, C. Simmons and L. Kozubowski, «Colony and Single Cell Level Analysis of
the Heterogeneous Response of Cryptococcus neoformans to Fluconazole, » Frontiers in
Cellular and Infection Microbiology, vol. 8, nº 203, 2018.

133

[49] K. Lee, Y. So, D. Yang, K. Jung, J. Choi, D. Lee, H. Kwon, J. Jang, L. Wang, S. Cha, G.
Meyers, E. Jeong,
J. Jin, Y. Lee, J. Hong, S. Bang, J. Ji, G. Park, H. Byun, S. Park, Y. Park, G. Adedoyin, T.
Kim, A. Averette, J. Choi, J. Heitman, E. Cheong, Y. Lee and Y. Bahn, «Systematic
functional analysis of kinases in the fungal pathogen Cryptococcus neoformans, » Nature
Communications, vol. 7, 2016.
[50] M. Kim, S. Kim, J. Yoon, Y. Lee and Y. Bahn, «An efficient gene-disruption method in
Cryptococcus neoformans by double-joint PCR with NAT-split markers., » Biochem
Biophys Res Commun., vol. 390, nº 3, pp. 983-988, 2009.

134

V. Conclusions and Future Directions

This chapter will conclude our study into the factors that regulate titanization in
Cryptococcus neoformans and our elucidation of the Swe1 homologs in this fungal
pathogen. We will summarize our findings in relation to the research aims and questions
and discussing the value of this work. We will also review the limitations of this study and
propose opportunities for future studies.

5.1 On titanization
This study aimed to answer two questions: what are the minimum in vitro
conditions to cause C. neoformans/gatiii to titanize, as well as to investigate if other
members of Cryptococcus spp. could titanize. Regarding the latter, results in chapter 2
suggest that, at least in vitro, only members of the C. neoformans/gattii species
complexes are capable of undergoing titanization. This suggests that Titan Cell formation
could be an adaptation of the species complex to survive the host environment and the
hosts

immune

system.

Regarding

the

minimum

conditions

needed

for

C.

neoformans/gattii to undergo titanization, the results in Chapter 3 suggest that the
formation of these Titan or Titan-like cells can be induced by the shift from a low nutrient
media into restrictive conditions for proliferation. The data suggest that a high sensitivity
to alkaline pH (>7.3) helps account for why C. neoformans/gattii form Titan-like cells, while
incubating at conditions that restrict proliferation with 5% CO2 at 37˚C. Since those two
chapters have been published as papers, we refer the reader to chapter 2 and 3 to learn
more about the limitations and future directions for these projects.
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5.2 On elucidation of the Wee1 homologs in C. neoformans
For such an important fungal pathogen, research into the cell cycle of C.
neoformans and how it relates to virulence has been far and few in between. How the
yeast organizes and regulates its cell cycle, can provide a clearer picture of all the
mechanisms that make it a successful opportunistic pathogen. Our research suggests
that the Wee1 homologs, CnSwe1 and CnSwe102 have an important role in regulating
cell cycle progression and the activation and resolution of cell cycle checkpoints. The
Cnswe1∆ and Cnswe102∆ strains respond to DNA damaging agents by increasing their
ploidy levels, with a sharp increase in what appears to be the S-phase. Our data suggest
that these two homologs have a role in the S-phase checkpoint and in the G2/M DNA
damage checkpoint. The heterologous expression of the C. neoformans Wee1
homologues in S. cerevisiae suggest they can phosphorylate the CDK on the conserved
residue and our results also point to a redundancy in cell cycle control roles for these
Wee1 homologues.

5.2.1 Limitations of this study
In general, our knowledge on the intricacies of cell cycle control in C. neoformans
is lacking. We did not address any direct role or mechanistic aspects of CnSwe1 and
CnSwe102 in the G2/M checkpoint, partially due to a lack of facilities and funding. We
did not address the roles of the homologs in S-phase, as it was beyond the scope of our
study. Finding that they most likely have a role in S-phase reveals a need for rethinking
both the cell cycle control and direct DNA repair functions of CnSwe1 or CnSwe102. No
inhibitor of the Wee1 family was used in this research project. This gives us a need for
testing the effects of Wee1 inhibitors, such as MK-1775, in the single deletion mutants,
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since complete depletion of Swe1 under the control of the CTR4 copper promoter was
not achieved.

5.2.2 Future Directions
There are several preeminent questions regarding the roles of Swe1/Swe102
and how this relates to virulence in C. neoformans. The WT and/or the single deletion
mutants, Cnswe1∆ and Cnswe102∆, should be treated with different Wee1 inhibitors
such as MK-1775, ZN-c3, or ZNL 02-096. Since these drugs are specific inhibitors for
Wee1 in humans, they should be tested against our single deletion mutants and the
possible S-phase checkpoint activation should be analyzed through qPCR, Western
Blot, and flow cytometry. The S-phase checkpoint seemed to be activated in the single
deletion mutants after treatment with DNA damaging agents. Treating these strains with
both DNA damaging agents and a Wee1 inhibitor will allow us to see if the checkpoint is
activated at all. If the checkpoint is abrogated, mitotic catastrophe should occur,
resulting in the single deletions dying off completely.
The mitotic inhibitors would also allow us to evaluate if the CTR4 promoter used
in this study can continue to be a viable option for research into Swe1/Swe102. With the
inhibitors we would be able to compare the levels of the homologs and the levels of
phosphorylation of CDK1 when the Wee1 homologs are completely inhibited. Treatment
with the inhibitors should completely eliminate CnSwe1/CnSwe102 activity, allowing for
a better analysis of the functions of these proteins in the DNA damage and S-phase
checkpoints. This wealth of new knowledge should allow us to better understand C.
neoformans and hopefully bring us closer to being able to control cryptococcosis.
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